<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B - Olasupo, OO - 2021 | Cochrane Library</title> <meta content="Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B - Olasupo, OO - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014201/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B - Olasupo, OO - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014201/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014201" name="dc.identifier" scheme="DOI"/> <meta content="Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B" name="citation_title"/> <meta content="Omotola O Olasupo" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Megan S Lowe" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Ashma Krishan" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Peter Collins" name="citation_author"/> <meta content="School of Medicine, Cardiff University" name="citation_author_institution"/> <meta content="Alfonso Iorio" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Davide Matino" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="davide.matino@yahoo.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD014201" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014201/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014201/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014201/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Blood Coagulation Factors [*therapeutic use]; Factor VIII [*therapeutic use]; Hemarthrosis [*prevention &amp; control]; Hemophilia A [*complications]; Hemophilia B [*complications]; *Pharmaceutical Preparations" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014201&amp;doi=10.1002/14651858.CD014201&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014201\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014201\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014201",title:"Clotting factor concentrates for preventing bleeding and bleeding\\u2010related complications in previously treated individuals with haemophilia A or B",firstPublishedDate:"Aug 18, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014201&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014201';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014201/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014201/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014201%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014201/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014201/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014201/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014201/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014201" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014201/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014201" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014201/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014201/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2681 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014201" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0113"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-sec-0107"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014201/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/appendices#CD014201-sec-0118"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/supinfo/CD014201StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/supinfo/CD014201StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014201/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014201/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014201/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014201/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014201/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0004">Omotola O Olasupo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0005">Megan S Lowe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0006">Ashma Krishan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0007">Peter Collins</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0008">Alfonso Iorio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014201/information#CD014201-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Davide Matino</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014201/information/en#CD014201-sec-0123">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014201/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014201">https://doi.org/10.1002/14651858.CD014201</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014201-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014201-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014201-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014201-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014201-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014201-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014201-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014201-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014201-abs-0001" lang="en"> <section id="CD014201-sec-0001"> <h3 class="title" id="CD014201-sec-0001">Background</h3> <p>The hallmark of severe hemophilia (A or B) is recurrent bleeding into joints and soft tissues with progressive joint damage, despite on‐demand treatment. Prophylaxis has long been used, but not universally adopted, because of medical, psychosocial, and cost controversies. </p> </section> <section id="CD014201-sec-0002"> <h3 class="title" id="CD014201-sec-0002">Objectives</h3> <p>To determine the effectiveness of clotting factor concentrate prophylaxis in managing previously‐treated individuals with hemophilia A or B. </p> </section> <section id="CD014201-sec-0003"> <h3 class="title" id="CD014201-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. In addition, we searched MEDLINE and Embase and online trial registries. </p> <p>Most recent search of Group's Coagulopathies Trials Register: 24 February 2021.</p> </section> <section id="CD014201-sec-0004"> <h3 class="title" id="CD014201-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and quasi‐RCTs evaluating people with hemophilia A or hemophilia B, who were previously treated with clotting factor concentrates to manage their hemophilia. </p> </section> <section id="CD014201-sec-0005"> <h3 class="title" id="CD014201-sec-0005">Data collection and analysis</h3> <p>Two authors independently reviewed trials for eligibility, assessed risk of bias and extracted data. The authors used the GRADE criteria to assess the certainty of the evidence. </p> </section> <section id="CD014201-sec-0006"> <h3 class="title" id="CD014201-sec-0006">Main results</h3> <p>Ten trials (including 608 participants) were eligible for inclusion. Eight of the trials (477 participants) had arms comparing two or more prophylactic regimens to one another and four of the trials (n = 258) compared prophylaxis to on‐demand treatment (two trials had multiple arms and were included in both comparisons). </p> <p><b>Comparison of two or more prophylactic regimens</b> </p> <p>For trials comparing one prophylaxis regimen to another, given the heterogeneity of the data, none of the data were pooled for this comparison. Considering the individual trials, three trials reported the primary outcome of joint bleeding, and none showed a dfference between dosing regimens (low‐certainty evidence). For the secondary outcome of total bleeding events, prophylaxis with a twice‐weekly regimen of FIX likely results in reduced total bleeds compared to a once‐a‐week regimen of the same dose, mean difference (MD) 11.2 (5.81 to 16.59) (one trial, 10 participants, low‐certainty evidence). </p> <p>Transient low‐titer anti‐FVIII inhibitors were reported in one of the trials. Blood‐transmitted infections were not identified. Other adverse events reported include hypersensitivity, oedema, and weight gain. These were, however, rare and unrelated to study drugs (very low‐certainty evidence). </p> <p><b>Comparison of prophylactic and on‐demand regimens</b> </p> <p>Four of the trials (258 participants) had arms that compared prophylaxis to on‐demand treatment. Prophylaxis may result in a large decrease in the number of joint bleeds compared to on‐demand treatment, MD ‐30.34 (95% CI ‐46.95 to ‐13.73) (two trials, 164 participants, low‐certainty evidence). One of these trials (84 participants) also reported the long‐term effects of prophylaxis versus on‐demand therapy showing improved joint function, quality of life, and pain; but no differences between groups in joint structure when assessed by magnetic resonance imaging (MRI). </p> <p>In one trial (84 participants) validated measures for joint health and pain assessment showed that prophylaxis likely improves joint health compared to an on‐demand regimen with an estimated change difference of 0.94 points (95% CI 0.23 to 1.65) and improves total pain scores, MD ‐17.20 (95% CI ‐27.48 to ‐6.92 (moderate‐certainty evidence). </p> <p>Two trials (131 participants) reported that prophylaxis likely results in a slight increase in adverse events, risk ratio 1.71 (1.24 to 2.37) (moderate‐certainty evidence). No inhibitor development and blood‐transmitted infections were identified. </p> <p>Overall, the certainty of the body of evidence was judged to be low because of different types of bias that could have altered the effect. </p> <p> </p> </section> <section id="CD014201-sec-0007"> <h3 class="title" id="CD014201-sec-0007">Authors' conclusions</h3> <p>There is evidence from RCTs that prophylaxis, as compared to on‐demand treatment, may reduce bleeding frequency in previously‐treated people with hemophilia. Prophylaxis may also improve joint function, pain and quality of life, even though this does not translate into a detectable improvement of articular damage when assessed by MRI.  </p> <p>When comparing two different prophylaxis regimens, no significant differences in terms of protection from bleeding were found. Dose optimization could, however, result in improved efficacy. Given the heterogeneity of the data, pooled estimates were not obtained for most comparisons.  </p> <p>Well‐designed RCTs and prospective observational controlled studies with standardised definitions and measurements are needed to establish the optimal and most cost‐effective treatment regimens. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014201-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014201-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014201-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014201-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014201-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014201-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014201-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014201-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014201-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014201-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014201-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014201-abs-0002" lang="en"> <h3>Regular clotting factor replacement therapy to prevent joint damage in people living with severe hemophilia A or B </h3> <p><b>Review question</b> </p> <p>Should people, who have previously been treated for joint bleeding, be given regular preventative treatment with clotting factor concentrates to manage their condition? </p> <p><b>Background</b> </p> <p>Hemophilia A and B are X‐linked inherited bleeding disorders in which bleeding  into joints is a major problem. Repeated joint bleeds can lead to affected joints (commonly referred to as 'target joints') becoming damaged and painful, with limited movement. Currently, bleeding is treated and prevented with plasma‐derived or recombinant clotting factor concentrates, and more recently non‐clotting factor formulations. This review looked at how useful and effective different clotting factor treatment strategies are for preventing joint bleeding and other outcomes in previously treated people with hemophilia A or B. </p> <p><b>Search date</b> </p> <p>Date of last search: 24 February 2021.</p> <p><b>Study characteristics</b> </p> <p>This review includes 10 randomised controlled trials. Eight had treatment arms that compared the regular use of clotting factor concentrates to prevent joint bleeds with different dosing schemes to identify regimens that may be better; four had treatment arms that compared the regular use of factor concentrates to prevent bleeds to their 'on demand' use to treat bleeds once they occur (two trials had multiple arms and were included in both comparisons). </p> <p><b>Key results</b> </p> <p>In people living with hemophilia A or B previously treated for joint bleeding or with existing joint damage, preventive therapy may reduce the number of joint bleeds compared to 'on‐demand therapy'. This reduction in bleeds may lead to an improvement in joint function, pain, and quality of life. However, preventive therapy is linked to an increased use of factor concentrates and therefore higher treatment costs. Further studies are needed to establish the best preventive course of treatment in terms of starting time, frequency and dose level. </p> <p><b>Certainty of the evidence</b> </p> <p>Overall, the certainty of the evidence was judged to be low because of different types of bias that could have affected the results. Future research might have an important role in changing our confidence in these results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014201-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014201-sec-0113"></div> <h3 class="title" id="CD014201-sec-0114">Implications for practice</h3> <section id="CD014201-sec-0114"> <p>There is evidence from randomised controlled trials that the use of prophylactic clotting factor concentrate may result in reduced frequency of total bleeds, and likely improves joint function and quality of life in people with severe or moderate haemophilia A and B. </p> </section> <h3 class="title" id="CD014201-sec-0115">Implications for research</h3> <section id="CD014201-sec-0115"> <p>Prophylaxis treatment is often considered the ideal treatment in high‐resource countries. However, there are still knowledge gaps in the understanding of haemophilia treatment with respect to the ideal regimen and when to start prophylaxis. While the results of this review begin to shed light on the use of secondary prophylaxis in managing bleeding, there are still areas that require elucidation, namely the impact of late prophylaxis in people with varying degrees of arthropathy at baseline, the most cost‐efficient dosage and frequency, the minimally effective dose and the role of individualised regimens to a person’s bleeding pattern and activity. Further research should be undertaken to attempt to provide evidence‐based data for these areas. </p> <p>Future randomised controlled trials should address the following aspects:</p> <p> <ol id="CD014201-list-0017"> <li> <p>comparative efficacy, safety, and effectiveness of different prophylactic regimens (escalating versus fixed‐dose, pharmacokinetic‐tailored versus fixed‐dose); </p> </li> <li> <p>standardised clinical and radiological outcome measures of efficacy;</p> </li> <li> <p>long‐term cost‐effectiveness;</p> </li> <li> <p>Individualisation of regimens.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014201-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014201-sec-0008"></div> <div class="table" id="CD014201-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison of two prophylaxis regimens</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis regimen compared with another prophylaxis regimen for previously treated individuals with haemophilia A or B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children or adults with hemophilia A or B </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: secondary prophylaxis </p> <p><b>Comparison</b>: secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of joint bleeding episodes per year (AJBR) </p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference was seen between prophylaxis regimens in any of the studies. Thrice‐weekly higher dose prophylaxis regimen compared to a twice‐weekly lower dose regimen, MD ‐1.70 (95% CI ‐5.06 to 1.66) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>).  </p> <p> </p> <p>PK‐guided prophylaxis targeting trough levels of 8% to 12% compared to targeting trough levels of 1% to 3%, MD ‐1.50 (95% CI ‐3.54 to 0.54) (n = 115 participants) (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> <p> </p> <p>Low frequency prophylaxis (100 IU / kg once a week) compared to standard frequency regimen (50 IU / kg twice a week, MD of 1.70 (95% CI ‐1.09 to 4.49) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 participants</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to combine results in a meta‐analysis due to the different prophylaxis regimens used in each trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of total bleeds per year (ABR)</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was no difference in total number of bleeds between prophylactic regimens in five trials (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p> </p> <p>A twice‐a‐week regimen (7.5 IU/kg) was favoured over a once‐a‐week regimen (15 IU/kg), MD 11.20 (5.81 to 16.59) (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>) and a prophylaxis group with dosing producing at least 0.25 IU/mL of factor VIII showed a significant reduction in overall bleeding frequency compared to a dosing regimen producing at least 0.01IU/mL once weekly, MD 3.44 (95% CI 2.42 to 4.46) (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 participants</p> <p>(7 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to heterogeneity of intervention and design, none of the trials we were unable to combine data from any of the trials (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐related adverse events</p> <p> </p> <p>Follow‐up: 32 weeks to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported no difference in total treatment‐emergent adverse events, MD 1.00 (95% CI 0.54 to 1.84) at 32 weeks (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). A further trial reported no difference between treatment regimens in mean rates of adverse events (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). </p> <p>In the study targeting different trough levels, no serious adverse event was treatment‐related in the arm targeting trough levels of of 1% to ‐3%, and in the arm targeting trough levels of 8% to ‐12%, one serious adverse event was estimated to be treatment‐related (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 </p> <p>participants</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three trials did not report the rate of adverse events by treatment groups (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). The LEOPOLD II trial reported three treatment related  adverse events but gave no further detail (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> <p>There was no reported inhibitor development reported in six of the trials in this comparison (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>ABR</b> : annualised bleed rate; <b>AJBR</b> : annualised joint bleed rate; <b>CI</b> : confidence interval; <b>FIX</b> : factor IX; <b>RR</b> : risk ratio; <b>MD</b>: mean difference.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included trials, particularly across the domains of randomisation and allocation concealment. The trials were also considererd at high risk of bias due to lack of blinding <br/>b. Downgraded once due to imprecision as a result of small sample sizes. Although the total number of participants included in this outcome is 390, none of the studies could be combined and so we have based our assessment on the numbers in individual trials. The two trials that showed a difference between regimens included nine and 10 participants. </p> <p>c. Downgraded twice due to an unclear or high risk of bias across many of the domains with particular concern around randomisation procedures, allocation concealment and blinding. </p> <p>d. Downgraded once due to imprecision from small sample size and low event rates. Although the total number of participants is reasonable, none of the trials could be combined and so we have based our judgement on the numbers in the individual trials. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014201-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis with standard clotting factor concentrate compared with pegylated liposome FVIII formulation for previously treated individuals with haemophilia A</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children or adults with hemophilia A </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: prophylaxis using investigational BAY 79‐4980 </p> <p><b>Comparison</b>: standard secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis using investigational BAY 79‐4980</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AJBR</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of joint bleeding in the prophylaxis arm using investigational drug BAY 79‐4980 was 12.2. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of joint bleeding in the standard prophylaxis regimen (5.0), was 7.20 lower (11.01 lower to 3.39 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.20</p> <p>(‐11.01 to ‐3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More participants withdrew consent in the investigational drug arm. The trial was prematurely discontinued by the sponsor based on the recommendation of an independent data and safety monitoring board. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABR</p> <p> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of total bleeds in the prophylaxis arm using investigational drug BAY 79‐4980 was 15. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of total bleeds in the standard prophylaxis regimen (5.8), was 9.20 lower (13.07 lower to 5.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.20</p> <p>(‐13.07 to ‐5.33 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More participants withdrew consent in the investigational drug arm. The trial was prematurely discontinued by the sponsor based on the recommendation of an independent data and safety monitoring board. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any reported adverse effects</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No specific information was given about the presence/absence of adverse events in the BAY 70‐4980 group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>One participant in the prophylaxis group reported three serious adverse events, which were deemed to be drug related. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>ABR</b> : annualised bleed rate; <b>AJBR</b> : annualised joint bleed rate; <b>CI</b> : confidence interval; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low cerainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to high risk of bias due to attrition bias from incomplete outcome data.<br/>b. Downgraded once due to premature study discontinuation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014201-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylaxis regimen versus on‐demand treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis regimen compared with on‐demand treatment for previously treated individuals with haemophilia A or B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with haemophilia A or B </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: secondary prophylaxis </p> <p><b>Comparison</b>: on‐demand treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>On‐demand treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of joint bleeding episodes or joint bleeding frequency</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of joint bleeding episodes in the on‐demand treatment group was 34</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of joint bleeding episodes in the prophylaxis regimen group was 30.34 lower (46.95 lower to 13.73 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐30.34 (‐46.95 to ‐13.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The data from the A‐LONG trial suggests the same; however, these data were reported with medians, hence could not be included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of total bleeds per year or bleeding frequency</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of total bleeds in the on‐demand treatment group was 44</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of total bleeds in the prophylaxis regimen group was 40.24 lower (64.04 lower to 16.44 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐40.24 (‐64.04 to ‐16.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The data from the A‐LONG trial suggests the same effect; however, these data were reported with medians, hence could not be included in the analysis (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>). </p> <p>When comparing the overall bleeding frequency in 9 participants in the Aronstam cross‐over trial, there was a significant reduction in the overall bleeding frequency in the prophylaxis group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any reported adverse events</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>415 per 1000 (27 per 65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>712 per 1000 (47 per 66)</p> <p>The number of participants with adverse events in the prophylaxis regimen group was 1.71 times higher (1.24 times higher to 2.37 times higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.71</p> <p>(1.24 to 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The 2 trials were open‐label trials with unclear risk of bias for randomised sequence generation (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). </p> <p> </p> <p>The LEOPOLD II trial did not give the distribution of adverse events across groups, but there were 3 reported treatment‐related adverse events while no participant developed an inhibitor during the course of treatment (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). In the 1976 Aronstam trial, one participant developed antigen‐negative hepatitis and was removed from the remaining duration of the trial (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Th\e basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to high risk of bias due to performance and detection bias attributed to open‐label studies.<br/>b. Downgraded once due to high levels of heterogeneity across trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014201-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014201-sec-0009"></div> <section id="CD014201-sec-0010"> <h3 class="title" id="CD014201-sec-0010">Description of the condition</h3> <p>Congenital hemophilia is a rare x‐linked bleeding disorder caused by a deficiency in clotting factor VIII (FVIII) in hemophilia A and factor IX (FIX) in hemophilia B (<a href="./references#CD014201-bbs2-0104" title="SrivastavaA , SantagostinoE , DougallA , KitchenS , SutherlandM , PipeSW , et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia2020;26(Suppl 6):1-158.">Srivastava 2020</a>). Severity of disease is classified according to level of clotting factor naturally present in the blood: severe (with a baseline coagulation factor level of less than 1% of normal); moderate (with clotting factor levels of 1% to 5%); and mild (6% to 49%) (<a href="./references#CD014201-bbs2-0088" title="BlanchetteVS , KeyNS , LjungLR , Manco-JohnsonMJ , vanden BergHM , SrivastavaA , Subcommittee on Factor VIII , Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis2014;12(11):1935-9.">Blanchette 2014</a>). </p> <p>The physical manifestation of hemophilia varies with the severity of disease. People with mild and moderate hemophilia rarely experience spontaneous bleeding episodes, and often only bleed abnormally following trauma or in association with invasive procedures. People with severe hemophilia are at highest risk for experiencing frequent and severe spontaneous bleeding incidents. This group is also prone to experiencing recurrent or chronic bleeding into joints and muscles, which can develop into haemophilic joint arthropathy and muscle atrophy. </p> </section> <section id="CD014201-sec-0011"> <h3 class="title" id="CD014201-sec-0011">Description of the intervention</h3> <p>While there is no routinely‐available cure for hemophilia, symptoms of the disease can be effectively managed by the infusion of exogenous clotting factor concentrates (either FVIII or FIX). The availability of clotting factor concentrates has improved the morbidity, mortality and quality of life (QoL) of people with hemophilia (<a href="./references#CD014201-bbs2-0097" title="LusherJM . Prophylaxis in children with hemophilia: is it the optimal treatment?Thrombosis Haemostasis1997;78(1):726-9.">Lusher 1997</a>; <a href="./references#CD014201-bbs2-0106" title="TobaseP , LaneH , SiddiqiAE , Ingram-RichR , WardRS , Universal Data Collection Joint Outcome Working Group, Hemophilia Treatment Center Network (HTCN) Study Investigators. Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010). Haemophilia2016;22(4):604-14.">Tobase 2016</a>). Availability of factor concentrate allows for early treatment of acute bleeding incidents, and has resulted in a decrease in joint deformities in untreated or minimally‐treated individuals (<a href="./references#CD014201-bbs2-0085" title="AhlbergA . Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthopedic Scandinavian1965;77 Suppl 1:7-80.">Ahlberg 1965</a>; <a href="./references#CD014201-bbs2-0094" title="HilgartnerMW . Hemophilic arthropathy. Advances in Pediatrics1974;21:139.">Hilgartner 1974</a>; <a href="./references#CD014201-bbs2-0096" title="LiddleAD , Rodriguez-MerchanEC . Evidence-based management of the knee in hemophilia. JBJS Reviews2017;5(8):e12.">Liddle 2017</a>). </p> <p>Factor concentrates are generally administered according to two treatment regimens:</p> <p> <ol id="CD014201-list-0001"> <li> <p>on‐demand (also termed episodic) treatment, where individuals receive clotting factor only in response to a bleeding event; or </p> </li> <li> <p>prophylaxis treatment, where individuals receive regular infusions of clotting factor with the aim to prevent bleeds. </p> </li> </ol> </p> <p>A 1994 study by Aledort, showed that prophylaxis treatment reduced the number of bleeding events and may reduce the incidence of bleeding‐related adverse events, such as haemophilic arthropathy (<a href="./references#CD014201-bbs2-0011" title="AledortLM , HaschmeyerRH , PetterssonH , The orthopaedic outcome study group. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. Journal of Internal Medicine1994;236(4):391-9. ">Aledort 1994</a>). This same study showed progressive joint deterioration over the six‐year follow‐up period in participants using on‐demand treatment only (<a href="./references#CD014201-bbs2-0011" title="AledortLM , HaschmeyerRH , PetterssonH , The orthopaedic outcome study group. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. Journal of Internal Medicine1994;236(4):391-9. ">Aledort 1994</a>). Given its preferable outcomes, prophylaxis treatment, in comparison to on‐demand treatment, has been recommended for all children with severe hemophilia (<a href="./references#CD014201-bbs2-0086" title="BerntorpE , AstermarkJ , BjorkmanS , BlanchetteVS , FisherK , GiangrandePL , et al. Consensus perspectives in prophylactic therapy for haemophilia: summary statement. Haemophilia2000;9 Suppl 1:1-4.">Berntorp 2003</a>; <a href="./references#CD014201-bbs2-0098" title="National Hemophilia Foundation MASAC. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 107. www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&amp;contentid=582 (accessed 01 July 2010).">MASAC 2010</a>; <a href="./references#CD014201-bbs2-0099" title="National Hemophilia Foundation MASAC. MASAC Recommendation Concerning Prophylaxis. Document 241. www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-241-recommendation-concerning-prophylaxis (accessed July 6, 2021).">MASAC 2016</a>; <a href="./references#CD014201-bbs2-0101" title="RaymentR , ChalmersE , ForsythK , GoodingR , KellyAM , ShapiroS , et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. British Journal of Haematology2020;190(5):684-95.">Rayment 2020</a>; <a href="./references#CD014201-bbs2-0103" title="RichardsM , WilliamsM , ChalmersE , LiesnerR , CollinsP , VidlerV , et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. British Journal of Haematology2010;149(4):498-507.">Richards 2010</a>; <a href="./references#CD014201-bbs2-0104" title="SrivastavaA , SantagostinoE , DougallA , KitchenS , SutherlandM , PipeSW , et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia2020;26(Suppl 6):1-158.">Srivastava 2020</a>). </p> </section> <section id="CD014201-sec-0012"> <h3 class="title" id="CD014201-sec-0012">How the intervention might work</h3> <p>There are two main categories of prophylactic treatment: primary prophylaxis, which is established before joint deterioration (before the second clinically‐evident joint bleed and age three years); and secondary prophylaxis, which is established after some joint deterioration. Given the differences in starting times, the aims of primary and secondary prophylaxis differ. Primary prophylaxis aims to use regular infusions of factor concentrate to maintain the individuals' factor level above a desired target, usually in the mild or moderate range (above 1% of clotting factor present in blood), to prevent spontaneous bleeding episodes and joint arthropathy. Secondary prophylaxis aims to slow the progression of existing arthropathy, prevent the development of new arthropathies, and prevent further spontaneous bleeding incidents (<a href="./references#CD014201-bbs2-0091" title="HayCR . Prophylaxis in adults with haemophilia. Haemophilia2007;13 Suppl 2:10-5.">Hay 2007</a>). </p> <p>Secondary prophylaxis is generally started after some degree of joint arthropathy has already occurred (<a href="./references#CD014201-bbs2-0091" title="HayCR . Prophylaxis in adults with haemophilia. Haemophilia2007;13 Suppl 2:10-5.">Hay 2007</a>) and can theoretically be started at any time in life. The existing evidence shows that starting secondary prophylaxis in adulthood can reduce bleeding frequency, and delay the progression of joint arthropathy (<a href="./references#CD014201-bbs2-0078" title="TagliaferriA , FranchiniM , CoppolaA , RivoltaGF , SantoroC , RossettiG , et al. Effect of secondary prophylaxis started in adult and haemophiliacs. Haemophilia2008;14(5):945-51. ">Tagliaferri 2008</a>). For these reasons, the Medical and Scientific Advisory Council of the US National Hemophilia Foundation (MASAC) has identified that individuals, especially those with severe hemophilia, may benefit from continuing prophylaxis throughout their life (<a href="./references#CD014201-bbs2-0098" title="National Hemophilia Foundation MASAC. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document 107. www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&amp;contentid=582 (accessed 01 July 2010).">MASAC 2010</a>; <a href="./references#CD014201-bbs2-0099" title="National Hemophilia Foundation MASAC. MASAC Recommendation Concerning Prophylaxis. Document 241. www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-241-recommendation-concerning-prophylaxis (accessed July 6, 2021).">MASAC 2016</a>). </p> </section> <section id="CD014201-sec-0013"> <h3 class="title" id="CD014201-sec-0013">Why it is important to do this review</h3> <p>Despite the known benefits of prophylaxis, there are medical, psychosocial and cost barriers that preclude the universal use of prophylaxis (<a href="./references#CD014201-bbs2-0087" title="BlanchetteVS , Manco-JohnsonM , SantagostinoE , LjungR . Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia2004;10 Suppl 4:97-104.">Blanchette 2004</a>; <a href="./references#CD014201-bbs2-0105" title="ThornburgCD , DuncanNA . Treatment adherence in hemophilia. Patient Prefer Adherence2017;11:1677-86.">Thornburg 2017</a>). Such concerns may be balanced by strong evidence of the efficacy of prophylaxis treatment. Numerous studies exist citing the efficacy of primary prophylaxis and the previous systematic review (from which this review has been derived) showed that primary prophylaxis was significantly better at preserving joint function in children with hemophilia, in comparison to on‐demand treatment (<a href="./references#CD014201-bbs2-0095" title="IorioA , MarchesiniE , MarcucciM , StobartK , ChanAKC . Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD003429. [DOI: 10.1002/14651858.CD003429.pub4]">Iorio 2011</a>). Similar evidence, including evidence from randomised controlled trials, for the efficacy of secondary prophylaxis started in adulthood is accumulating, but has not yet been systematically reviewed. </p> <p>This review aims to clarify the efficacy and safety of secondary prophylaxis in adults by systematically reviewing and summarising the available evidence of prophylactic administration of factor concentrates in previously‐treated individuals with hemophilia A or B. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014201-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014201-sec-0014"></div> <p>To determine the effectiveness of clotting factor concentrate prophylaxis in managing previously treated individuals with hemophilia A or B, for improving short‐ and long‐term outcomes measured by one or more of the following. </p> <section id="CD014201-sec-0015"> <h3 class="title" id="CD014201-sec-0015">Short‐term outcomes</h3> <p> <ol id="CD014201-list-0002"> <li> <p>Number of joint bleeding episodes per year or bleeding frequency</p> </li> <li> <p>Number of total bleeds per year or bleeding frequency</p> </li> <li> <p>Clotting factor concentrate levels in plasma</p> </li> </ol> </p> </section> <section id="CD014201-sec-0016"> <h3 class="title" id="CD014201-sec-0016">Long‐term outcomes</h3> <p> <ol id="CD014201-list-0003"> <li> <p>Clinical joint function</p> </li> <li> <p>Orthopedic joint score</p> </li> <li> <p>Radiologic joint score</p> </li> <li> <p>QoL measurements</p> </li> </ol> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014201-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014201-sec-0017"></div> <section id="CD014201-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014201-sec-0019"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised controlled trials. All identified trials, unpublished or published as an article, an abstract or a letter, without any language limitations, were eligible for inclusion. </p> </section> <section id="CD014201-sec-0020"> <h4 class="title">Types of participants</h4> <p>Trials including individuals with congenital hemophilia A or B, receiving secondary prophylaxis were eligible. We included all trials which enrolled adults (aged 18 or over) and those trials with participants under 18 years of age if the participants met one of the three following criteria: </p> <p> <ol id="CD014201-list-0004"> <li> <p>proven haemophilic arthropathy;</p> </li> <li> <p>presence of one or more target joint;</p> </li> <li> <p>previous on‐demand treatment.</p> </li> </ol> </p> <p>We did not exclude based on degree of disease severity, type of previous treatment (if any), or presence of previous joint damage. Trials including participants with factor VIII or IX inhibitors at baseline were excluded.  </p> </section> <section id="CD014201-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We compared intravenous clotting factor concentrates administered as prophylactic treatment in any formulation (e.g. fresh frozen plasma, cryoprecipitate, lyophilised plasma‐derived clotting factor concentrate, or recombinant clotting factor concentrate), any concentration, any frequency and any dose, with no treatment, placebo, on‐demand treatment, or with one or more different prophylaxis regimens. We did not include trials of a single treatment and at least one treatment must have been a clotting factor concentrate. </p> <p>Therefore the anticipated comparison groups were as follows:</p> <p> <ul id="CD014201-list-0005"> <li> <p>prophylaxis versus prophylaxis with a different regimen;</p> </li> <li> <p>prophylaxis versus on‐demand treatment;</p> </li> <li> <p>prophylaxis versus no treatment;</p> </li> <li> <p>prophylaxis versus placebo.</p> </li> </ul> </p> </section> <section id="CD014201-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>The following primary and secondary outcomes were assessed based on clinical relevance.</p> <section id="CD014201-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD014201-list-0006"> <li> <p>Number of joint bleeding episodes or joint bleeding frequency during the trial</p> </li> <li> <p>Orthopedic joint score or clinical joint function</p> </li> <li> <p>QoL on validated scales (disease‐specific where possible)</p> </li> </ol> </p> </section> <section id="CD014201-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD014201-list-0007"> <li> <p>Number of total bleeding episodes or total bleeding frequency during the trial period</p> </li> <li> <p>Pain scores</p> </li> <li> <p>Radiologic joint score or radiologic measurements or descriptions of joint damage</p> </li> <li> <p>Clotting factor concentrate plasma levels</p> </li> <li> <p>Time loss to school or employment</p> </li> <li> <p>Integration into society (i.e. absenteeism)</p> </li> <li> <p>Scores on scales recording feeling of well‐being and global functioning</p> </li> <li> <p>Economic data: cost‐effectiveness, cost‐benefit, cost‐utilisation, cost‐minimisation</p> </li> <li> <p>Any reported adverse effects or toxicity of clotting factor concentrates (e.g. inhibitors, reactions, transmission of infection) </p> </li> </ol> </p> </section> </section> </section> <section id="CD014201-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD014201-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Coagulopathies Trials Register using the term: prophylaxis and (hemophilia* or haemophilia*). </p> <p>The Coagulopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE and the prospective handsearching of one journal ‐ Haemophilia. Unpublished work is identified by searching the abstract books of major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Congress of the World Federation of Hemophilia; the European Association for Haemophilia and Allied Disorders, the American Society of Gene and Cell Therapy and the International Society on Thrombosis and Haemostasis. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the most recent search of the Group's Coagulopathies Trials Register: 24 February 2021. </p> <p>We also searched the following databases and trial registries:</p> <p> <ol id="CD014201-list-0008"> <li> <p>MEDLINE Ovid (1946 to June 2016 – search carried out by authors of a previous version of this review </p> </li> <li> <p>Embase Ovid (1974 to June 2016 – search carried out by authors of a previous version of this review); </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>; searched 06 August 2020); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 06 August 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://apps.who.int/trialsearch" target="_blank">https://apps.who.int/trialsearch</a>; we were unable to carry out a search as access was temporarily unavailable due to the current COVID‐19 pandemic. We will try and search this resource when the review is updated). </p> </li> </ol> </p> <p>For details of the search strategies, please see (<a href="./appendices#CD014201-sec-0119">Appendix 1</a>). </p> </section> <section id="CD014201-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified for further references to relevant trials. </p> <p>The following conference proceedings were also hand searched:</p> <p> <ol id="CD014201-list-0009"> <li> <p>International Society for Thrombosis and Haemostasis Biannual Meeting (2004 to 2016);</p> </li> <li> <p>European Association for Haemophilia and Allied Disorders (2004 to 2016).</p> </li> </ol> </p> </section> </section> <section id="CD014201-sec-0028"> <h3 class="title" id="CD014201-sec-0028">Data collection and analysis</h3> <section id="CD014201-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two authors independently screened the titles and abstracts of the retrieved citations and retrieved all available complete manuscripts for potentially relevant trials. The same two authors assessed the full‐text manuscripts to select the final trials to be included according to the review's inclusion criteria. A third‐party arbitrator helped to settle any differences between the two authors. </p> </section> <section id="CD014201-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two authors independently extracted data using a pre‐designed data extraction form. The structured data form included the following information. </p> <p> <ul id="CD014201-list-0010"> <li> <p>Inclusion criteria of the trial</p> </li> <li> <p>Characteristics of the trial (i.e. trial design, location and time frame)</p> </li> <li> <p>Participant number and demographics</p> </li> <li> <p>The intervention and co‐interventions (including dosing and frequency of clotting factor concentrate) </p> </li> <li> <p>Outcomes (including primary and secondary outcome measures and description)</p> </li> <li> <p>Information regarding limitations and biases</p> </li> </ul> </p> <p>We considered any outcome data recorded as either individual events or as events grouped by time periods. </p> </section> <section id="CD014201-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The authors used the tool in RevMan 5.4 to measure the risk of bias and to produce summary figures (<a href="./references#CD014201-bbs2-0102" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2020</a>). </p> <p>The authors assessed the risk of bias using the 'Risk of bias' assessment tool as documented in section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014201-bbs2-0092" title="HigginsJP , AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). The following domains were assessed as having either a low, high, or unclear risk of bias: </p> <p> <ul id="CD014201-list-0011"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors);</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>To estimate selective outcome reporting, we identified original protocols and compared the results and outcomes reported in the final report to those proposed in the protocol. </p> </section> <section id="CD014201-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We anticipated that the primary outcome (number of joint bleeding episodes or joint bleeding frequency during the trial) would be reported using mean and standard deviation (SD). For the secondary outcomes, we anticipated continuous outcomes to be reported as either a rate of event, mean and SD, or median and interquartile range (IQR). We anticipated dichotomous outcomes to be reported as the frequency of each option. Given these assumptions, we measured the treatment effect of the primary outcome using a mean difference (MD). We measured the treatment effects of secondary outcomes using the risk difference (RD) or MD for continuous outcomes and risk ratio (RR) for dichotomous outcomes. We reported the 95% confidence interval (CI) of each measure of treatment effect.  </p> </section> <section id="CD014201-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We anticipated that the unit of analysis would be the individual, as disease progression and treatment can vary between individuals. Given the chronic nature of the condition, as well as the rapid onset and short duration of the intervention (factor VIII and IX physiological half‐lives are 12 and 24 hours respectively), we anticipated that some trials included would be cross‐over in design. We used the generic inverse variance (GIV) method to include cross‐over trials in any meta‐analyses conducted, as reported in chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014201-bbs2-0093" title="HigginsJP , EldridgeS , Li T (editors). Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). Whenever possible we have used individual patient data to analyze the results of cross‐over trials (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). In the Leopold II trial (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>) participants were randomised to receive on‐demand or prophylactic therapy with FVIII (two different regimens); participants were crossed‐over within their treatment groups, but only with respect to the methods for measuring the content of FVIII in the vials, therefore, we treated this trial as if it had a parallel design. </p> </section> <section id="CD014201-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact trial authors to provide any missing data. We reported the level of missing data and reason for missing data where possible. </p> </section> <section id="CD014201-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>Given the small number of trials that were included in a meta‐analysis in this review, we did not assess for heterogeneity in most of the analyses. However, where sufficient trials were included in a meta‐analysis,  we identified the presence of statistical heterogeneity using the Chi² value. We also reported the I² value as a measure of heterogeneity in the meta‐analysis. We applied the following thresholds, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014201-bbs2-0089" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>): </p> <p> <ul id="CD014201-list-0012"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: represents considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD014201-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>In future versions of this review, if there are more than 10 trials in the same analysis, we will construct a funnel plot and assess it for symmetry. </p> </section> <section id="CD014201-sec-0037"> <h4 class="title">Data synthesis</h4> <p>In comparisons where only one trial was assessed, we used the fixed‐effect model in the analyses. We used a random‐effects model in analyses including multiple trials to account for possible heterogeneity.  </p> </section> <section id="CD014201-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In future versions of this review, depending on data availability, we plan a subgroup analysis based on Pattersson scores and other measures indicating the extent of disease progression. </p> </section> <section id="CD014201-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to aggregate data for a majority of outcomes in this review. However, if there are a sufficient number of eligible and included trials, we will undertake a sensitivity analysis by looking at trials with a low risk of bias versus a high risk of bias, as measured above. </p> </section> <section id="CD014201-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented a summary of findings table for each of the following comparisons.</p> <p> <ol id="CD014201-list-0013"> <li> <p>Comparison between two prophylaxis regimens</p> </li> <li> <p>Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation </p> </li> <li> <p>Prophylaxis versus on‐demand comparison.</p> </li> </ol> </p> <p>The following outcomes were chosen based on relevance to clinicians and consumers and reported in the table. </p> <p> <ol id="CD014201-list-0014"> <li> <p>Number of joint bleeding episodes per year or bleeding frequency;</p> </li> <li> <p>Number of total bleeds per year or bleeding frequency;</p> </li> <li> <p>Any reported adverse event.</p> </li> </ol> </p> <p>We determined the certainty of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if we considered the limitation to be serious and by two levels if very serious. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014201-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014201-sec-0041"></div> <section id="CD014201-sec-0042"> <h3 class="title">Description of studies</h3> <p>Description of studies and results of the search are described below.</p> <section id="CD014201-sec-0043"> <h4 class="title">Results of the search</h4> <p>Our search strategies yielded 322 unique references, of which 68 articles reporting seven studies were included in this review (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). A further three trials (three articles) (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>) were accessed from a previous Cochrane Review (which this current review and one more Cochrane Review in progress, supersedes), and were also included in this review (<a href="./references#CD014201-bbs2-0095" title="IorioA , MarchesiniE , MarcucciM , StobartK , ChanAKC . Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD003429. [DOI: 10.1002/14651858.CD003429.pub4]">Iorio 2011</a>). No additional articles were found from searching reference lists of included articles or conference proceedings. </p> <p>We excluded a further 251 references to 89 trials. </p> </section> <section id="CD014201-sec-0044"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD014201-sec-0130" title="">Characteristics of included studies</a> for a full description of each trial. </p> <section id="CD014201-sec-0045"> <h5 class="title">Trial design</h5> <p>10 trials, with a total of 608 participants were included in the review (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a> (n = 47); <a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a> (n = 9); <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a> (n = 4); <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a> (n = 80); <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a> (n = 143); <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a> (n = 10); <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a> (n = 115); <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a> (n = 84); <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a> (n = 66); <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a> (n = 50). There was no disagreement between authors regarding trial relevance and inclusion. </p> <p>One trial was conducted in Italy (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>), two in England (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>) and seven were multicentre trials (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p>Four trials were cross‐over in design (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). In these trials, the order of intervention was randomised, and all participants received both the control and active treatment. All of the cross‐over trials included an adequate washout period before the second treatment intervention was administered. The remaining six trials were parallel in design, four trials were randomised open‐label trials (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>), one was a randomised double‐blind trial with an active control (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). The remaining randomised trial, the LEOPOLD II study, was reported as cross‐over, with participants randomised to one of six treatment arms (two low‐dose prophylaxis groups, two high‐dose prophylaxis groups, and two on‐demand treatment groups); participants received treatment based on CS/EP (chromogenic substrate assay per European Pharmacopoeia) or adjusted by a predefined factor to mimic results obtained with the one‐stage assay (CS/ADJ) for six months each with an intraindividual cross‐over after six months (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). However, since participants were crossed‐over within their treatment groups but only with respect to the methods for measuring the content of FVIII activity in the vials (using the CS/EP or the CS/ADJ). This cross‐over trial has been analysed as a parallel trial. </p> </section> <section id="CD014201-sec-0046"> <h5 class="title">Types of participants</h5> <p>All trials included participants receiving secondary prophylaxis. Two trials included individuals with hemophilia B: the Morfini trial included individuals with severe hemophilia B (FIX levels &lt; 1%) (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>); and the 2014 Valentino trial included individuals with moderately severe and severe hemophilia B (FIX levels ≤ 2%) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). Seven trials included individuals with severe haemophilia A only (FVIII levels &lt; 1% of normal) (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). One trial included participants with moderately severe to severe hemophilia A (FVIII levels ≤ 2% of normal) (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). All trials included participants who were previously exposed to FVIII or FIX, whether through on‐demand treatment or through a prophylaxis regimen. All included participants were males and between five years and 65 years of age. None of the participants had an inhibitory antibody to FVIII or FIX at baseline. </p> <p>There were some boys in the Aronstam 1976 trial who were also included in the 1977 trial: "Those boys who had been on the first double‐blind controlled trial (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>) and were still available for a further two terms were selected. There were four such boys, patients 1, 3, 8, and 9 of that trial. The boys selected had each had at least one full school term off prophylaxis before entering the second trial" (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>). </p> </section> <section id="CD014201-sec-0047"> <h5 class="title">Types of interventions</h5> <p>Two of the trials had multiple arms where a prophylaxis regimen was compared to another prophylaxis regimen, as well as a comparison of a prophylaxis and on‐demand regimen (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). Therefore, we included these two trials in two comparisons. </p> <section id="CD014201-sec-0048"> <h6 class="title">Comparison between two prophylaxis regimens</h6> <p>Eight trials compared two different prophylactic regimens (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>: <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). Of these, four trials had a fixed prophylaxis dose in both arms (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). We describe the intervention and comparison in the included trials below. </p> <p><a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>: prophylaxis arm A: sufficient dose to increase the FVIII level to 10% of normal versus prophylaxis arm B: sufficient dose to raise the FVIII level to 30% of normal. </p> <p><a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>: prophylaxis arm A: sufficient dose to increase FVIII levels to &gt;/= 0.25 IU/mL versus prophylaxis arm B: sufficient dose to increase FVIII levels to &gt;/= 0.1 IU/mL once weekly. </p> <p><a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>: prophylaxis arm A: FIX 7.5 U/kg twice per week versus prophylaxis arm B: FIX 15 U/kg once per week. </p> <p><a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>: prophylaxis arm A: standard prophylactic treatment of 20 to 40 IU/kg FVIII every 48 hours versus prophylaxis arm B: PK‐tailored prophylactic treatment of 20 to 80 IU/kg FVIII every 72 hours (dose‐dependent on PK evaluation). </p> <p><a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>: prophylaxis arm A: high‐dose regimen (FVIII 30 to 40 IU/kg thrice‐weekly versus prophylaxis arm B: low‐dose regimen (FVIII 20 to 30 IU/kg twice‐weekly). The factor concentrate used was an experimental full‐length rFVIII product referred to as BAY 81‐8973. This product was created to improve clinical efficacy by alterations in glycosylation and was also free of any human or animal‐derived products. BAY 81‐8973 was co‐expressed with heat shock protein 70 to improve the in vivo viability of the product. </p> <p><a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>: prophylaxis arm A: the investigational drug, BAY 79‐4980 consisting of 35 IU/kg of rFVIII and 13 mg/kg of pegylated liposome, administered at a reduced frequency of once per week versus prophylaxis arm B: standard prophylaxis treatment with rFVIII at a dose of 25 IU/kg three times per week. </p> <p><a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>: prophylaxis arm A: high‐frequency schema (50 IU/kg twice‐weekly) versus prophylaxis arm B: low‐frequency schema (100 IU/kg once‐weekly). </p> <p><a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>: prophylaxis arm A: PK‐guided prophylaxis to achieve FVIII trough levels of 1% to 3% versus treatment arm B: prophylaxis targeting trough levels of 8% to 12%. </p> </section> <section id="CD014201-sec-0049"> <h6 class="title">Prophylaxis regimen compared to on‐demand (episodic) treatment</h6> <p>Four trials compared on‐demand treatment to prophylaxis treatment (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p><a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>: on‐demand treatment administered on the basis of investigator recommendations versus prophylaxis treatment administered at a dosage of 25 IU/kg three times per week. This amount could be increased to a maximum of 35 IU/kg over two years in participants with 12 or more bleeding episodes per year on the trial. </p> <p><a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>: on‐demand treatment administered at a dose of 10 to 50 IU/kg FVIII as needed versus standard prophylaxis administered at a dose of 65 IU/kg rFVIII once weekly. Additionally, this trial also enrolled individuals who were previously on prophylaxis or on‐demand therapy but not willing to be randomised (Arm 1) to be treated with an individualized prophylaxis regimen (N = 118). Since this was a non‐randomised arm we did not include it in the analysis. </p> <p><a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>: prophylaxis A: high‐frequency schema (50 IU/kg twice‐weekly) versus prophylaxis B: low‐frequency schema (100 IU/kg once‐weekly). These two regimens were compared to an on‐demand treatment where FIX was given to treat bleeding events as needed. The factor product used for all study arms was nonacog alfa (BeneFIX). </p> <p><a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>: on‐demand treatment with BAY 81‐8973, a recombinant factor VIII product, was compared with two arms of prophylaxis treatment (prophylaxis A: high‐dose regimen (FVIII 30 to 40 IU/kg thrice‐weekly and prophylaxis B: low‐dose regimen (FVIII 20 to 30 IU/kg twice‐weekly). </p> </section> </section> <section id="CD014201-sec-0050"> <h5 class="title">Types of outcomes</h5> <p>Our primary outcome of interest, joint bleeding events or joint bleeding frequency, was reported in seven out of the 10 studies (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). Clinical joint function and radiologic measurements were reported in two trials (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Two trials also reported conducting QoL measurements (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>) and one trial (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>) reported the results of pain assessment. </p> <p>Overall bleeding events or overall bleeding frequency were reported in all 10 trials. The quantity of factor concentrate used was reported in four trials (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). Adverse event reporting, including the development of inhibitors, was reported in seven of the trials (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </section> </section> <section id="CD014201-sec-0051"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD014201-sec-0131" title="">Characteristics of excluded studies</a> for more details of the excluded trials. </p> <p>We excluded 89 trials (251 references) from this review. A total of 40 trials were excluded because they were not randomised studies, including 22 prospective and 18 retrospective observational studies. 15 trials had an intervention arm that included non‐clotting factors, e.g. concizumab (n = 9), emicizumab (n = 5), investigational RNA inteference therapeutic (n = 1). Six trials were excluded because they were conducted in participants with inhibitors, 13 additional trials were not eligible because they included individuals on primary prophylaxis. 10 trials assessed pharmacokinetic parameters and four were reported in conference abstracts only and detailed descriptions of trial participants were not available. One trial was a feasibility study with no hypothesis testing, no useable results and concluded that the trial lacked feasibility. </p> </section> </section> <section id="CD014201-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>We present an overall risk of bias assessment graphically in the figures section (<a href="#CD014201-fig-0001">Figure 1</a>; <a href="#CD014201-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD014201-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014201-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014201-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014201-sec-0053"> <h4 class="title">Allocation</h4> <section id="CD014201-sec-0054"> <h5 class="title">Random sequence generation</h5> <p>While all trial reports indicated that the trial was randomised, only four of the 10 included trials provided some detail of the method used for random sequence generation (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). In two of these trials, the method used was judged to be sound and of low risk of bias (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). Eight trials were judged to be of unclear risk of bias. </p> </section> <section id="CD014201-sec-0055"> <h5 class="title">Allocation concealment</h5> <p>Four trials indicated the method for allocation concealment; these were judged to be at low risk of bias for this domain (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). The remaining six trials had an unclear risk of bias (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </section> </section> <section id="CD014201-sec-0056"> <h4 class="title">Blinding</h4> <section id="CD014201-sec-0057"> <h5 class="title">Performance and detection bias</h5> <p>Three of the included trials employed an appropriate method to blind participants and personnel to minimise performance bias (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). The remaining seven trials were open‐label and we judged these to be at high risk of bias (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). In the Manco‐Johnson trial, bleeding events were patient‐reported using an electronic diary, but for other outcomes such as the MRI evaluation of hemophilic arthropathy by radiologists and the joint physical examination performed by the physiotherapists, the assessors were blinded. The open‐label trial design may also have influenced the results of the HRQoL (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Similarly, in the Morfini trial, even though this is an open‐label trial, it is reported that the assessors of orthopedic and radiological outcomes were blinded (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). </p> </section> </section> <section id="CD014201-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Eight of the 10 included trials either had no missing data or the losses to follow‐up were balanced and explained. We judged these trials to be at low risk of bias (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). One included trial had dropouts not balanced across groups and with the reason cited as “PK results”. Since this seems to be a treatment‐related difference, we judged this to be at a high risk of bias (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). The LipLong trial was prematurely discontinued by the sponsor based on the recommendation of an independent data and safety monitoring board and was analysed per protocol (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). Also, higher consent withdrawal was reported in the investigational drug arm (N = 8 versus N = 2). </p> </section> <section id="CD014201-sec-0059"> <h4 class="title">Selective reporting</h4> <p>We judged all included trials to have a low risk of bias for this domain. The protocols were not available in four of the 10 trials, but all expected outcomes were reported in these trials (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). We acquired the protocols for five trials and there was agreement between the outcomes outlined in the protocol and those presented in the final reports (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). For one trial, authors provided a three‐month timeframe from the time of request to make the protocol available; all expected and stated outcomes in this trial were, however, reported (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> </section> <section id="CD014201-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>In three of the cross‐over trials, the washout period was unclear, therefore we judged these to have an unclear risk of bias (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>, <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>).  The Liplong trial is marked high risk for other potential sources of bias due to the possibility of over‐estimation or "freezing‐effect" that could arise from premature discontinuation of clinical trials (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0107" title='WangH , RosnerGL , GoodmanSN . Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. Clinical Trials2016;13(6):621-31.'>Wang 2016</a>). In the remaining six trials, we did not identify any other potential sources of bias and so marked them as low risk for other potential sources of bias <a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </section> </section> <section id="CD014201-sec-0061"> <h3 class="title" id="CD014201-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD014201-tbl-0001"><b>Summary of findings 1</b> Comparison of two prophylaxis regimens</a>; <a href="./full#CD014201-tbl-0002"><b>Summary of findings 2</b> Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation</a>; <a href="./full#CD014201-tbl-0003"><b>Summary of findings 3</b> Prophylaxis regimen versus on‐demand treatment</a> </p> <section id="CD014201-sec-0062"> <h4 class="title">Comparison between two prophylaxis regimens</h4> <p>The certainty of the evidence has been graded for those outcomes included in the summary of findings table (<a href="./full#CD014201-tbl-0001">summary of findings Table 1</a>). For the definitions of these gradings, please refer to the summary of findings tables. </p> <p>We included eight trials (477 participants) in this comparison (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). One of the included trials compared a standard prophylaxis treatment regimen to a PK‐tailored regimen (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). One trial compared prophylaxis with a standard therapeutic factor concentrate to a pegylated liposome FVIII formulation (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>), this comparison is reported separately below. Overall, given the heterogeneity in reporting these trials, we did not aggregate data. </p> <section id="CD014201-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD014201-sec-0064"> <h6 class="title">1. Number of joint bleeding episodes or joint bleeding frequency</h6> <p>Three included trials reported on joint bleeding (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). The LEOPOLD II trial found no difference in joint bleed prevention when a thrice‐weekly, higher‐dose prophylaxis regimen was compared to a twice‐weekly (at 12 months follow‐up) lower‐dose prophylaxis, MD ‐1.70 (95% CI ‐5.06 to 1.66) (59 participants) (moderate‐certainty evidence) (<a href="./references#CD014201-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). Comparing a PK‐guided prophylaxis regimen targeting trough levels of 8% to 12% or 1% to 3% in the PROPEL III trial, no difference was also found between the two prophylaxis arms (at 12 months follow‐up); MD ‐1.50 (95% CI ‐3.54 to 0.54) (115 participants) (moderate‐certainty evidence) (<a href="./references#CD014201-fig-0004" title="">Analysis 1.2</a>) (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). No difference was also seen in spontaneous joint bleeds between the two regimens, MD ‐1.50 (95% CI ‐3.22 to 0.22) (<a href="./references#CD014201-fig-0005" title="">Analysis 1.3</a>) (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). In the Valentino 2014 trial, no difference was also reported in annualized joint bleeding in the low‐frequency prophylaxis arm (100 IU/kg once weekly) compared to the standard frequency regimen (50 IU/kg twice weekly); MD of 1.70 (95% CI ‐1.09 to 4.49) (50 participants) (<a href="./references#CD014201-fig-0006" title="">Analysis 1.4</a>) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </section> <section id="CD014201-sec-0065"> <h6 class="title">2. Orthopedic joint score or clinical joint function</h6> <p>One included (cross‐over) trial (10 participants) assessed joint function (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). While joint evaluations were conducted, data were not presented for individual treatment groups, rather results were presented that encompassed both arms. It was noted that through the 12 months of replacement therapy, range of motion was improved in 23 of 26 target joints. As well, there was also no deterioration in any joint, target or normal, over the course of treatment. </p> </section> <section id="CD014201-sec-0066"> <h6 class="title">3. QoL on validated scales</h6> <p>One included trial (66 participants) assessed QoL using the SF36v1 scale (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). Data for individual treatment arms were not provided. Rather trial authors stated that there was no difference in overall QoL between prophylactic regimens. </p> </section> </section> <section id="CD014201-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD014201-sec-0068"> <h6 class="title">1. Number of total bleeding episodes or total bleeding frequency</h6> <p>Given the differences in treatment regimens and populations, we did not pool data for these trials and instead we report the results individually. </p> <p>Seven trials reported on total bleeding. When comparing the use of a thrice‐weekly, higher‐dose prophylaxis with a twice‐weekly, lower‐dose prophylaxis regimen (at 12 months follow‐up), results suggested no difference in overall bleeding rate, MD ‐1.40 (95% CI ‐4.91 to 2.11) (moderate‐certainty evidence) (<a href="./references#CD014201-fig-0007" title="">Analysis 1.5</a>) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). There was also no difference seen in total bleeding between prophylaxis to increase FVIII level to 30% or 15%, MD 10.20 (95% CI ‐1.29 to 21.69) (<a href="./references#CD014201-fig-0008" title="">Analysis 1.6</a>) (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>). </p> <p>Comparing a standard prophylaxis regimen to a PK‐tailored regimen, no reduction in bleeds across the comparison was indicated, MD ‐0.30 (95% CI ‐0.86 to 0.26) (66 participants) (<a href="./references#CD014201-fig-0009" title="">Analysis 1.7</a>) (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). When considering the effect of prophylaxis on 10 participants with haemophilia B, we see that the twice‐a‐week regimen (7.5 IU/kg) was favoured over the once‐a‐week regimen (15 IU/kg), MD 11.20 (5.81 to 16.59) (moderate‐certainty evidence) (<a href="./references#CD014201-fig-0010" title="">Analysis 1.8</a>) (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). In the 2014 Valentino trial, comparing two different dosing frequencies in people with haemophilia B, only a P value of 0.22 was reported in the comparison of the two treatment regimens (50 IU/kg twice‐weekly versus 100 IU/kg once‐weekly) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p>When comparing the overall bleeding frequency in nine participants in the Aronstam cross‐over trial, there was a significant reduction in the overall bleeding frequency in the prophylaxis group with dosing producing at least 0.25 IU/mL of factor VIII compared to the dosing producing at least 0.01 IU/mL once weekly, MD 3.44 (95% CI 2.42 to 4.46) (<a href="./references#CD014201-fig-0011" title="">Analysis 1.9</a>) (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> <p>In the comparison between the prophylactic arm targeting trough levels of 1% to 3% or 8% to 12% in the PROPEL III trial, no difference was seen in bleeding frequency between the two groups, MD 2.00 (95% CI ‐0.13, 4.13) (115 participants) (<a href="./references#CD014201-fig-0012" title="">Analysis 1.10</a>) (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> </section> <section id="CD014201-sec-0069"> <h6 class="title">2. Pain scores</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD014201-sec-0070"> <h6 class="title">3. Radiologic joint score or radiologic measurements or descriptions of joint damage</h6> <p>Only one trial (10 participants) reported this outcome (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). Trial authors stated that the 12 months of prophylaxis treatments improved the radiological picture in six cases with grade II or III arthropathy, but had no effect in those with grade IV arthropathy, but no numeric data were given. </p> </section> <section id="CD014201-sec-0071"> <h6 class="title">4. Clotting factor concentrate plasma levels</h6> <p>One included trial (115 participants) assessed clotting factor concentrate plasma levels (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). In this trial, initial PK assessments showed mean (SD) plasma half‐lives (t½) of 15.3 (4.2) and 14.7 (5.1) hour in the 1% to 3% and 8% to 12% arms to be respectively. FVIII activity was a median (Q1 to Q3) 17.30 (15.2‐21.7) and 35.0 (29.2 ‐ 40.9) IU/dL during the first six months, and 17.30 (14.5 ‐ 22.4) and 30.9 (24.9 ‐ 41.2) IU/dL during the second six months for the 1% to 3% and 8% to 12% arms, respectively. Observed FVIII activity trough levels during the second six months were within the intended ranges of 1% to 3% and 8% to 12%; with median FVIII troughs ranging from 2.1 to 3.0 IU/dL and 10.7 to 11.7 IU/dL. </p> </section> <section id="CD014201-sec-0072"> <h6 class="title">5. Time loss to school or employment</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD014201-sec-0073"> <h6 class="title">6. Integration into society</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD014201-sec-0074"> <h6 class="title">7. Scores on scales recording feeling of well‐being and global functioning</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD014201-sec-0075"> <h6 class="title">8. Economic data</h6> <p>None of the included trials reported this outcome.</p> </section> <section id="CD014201-sec-0076"> <h6 class="title">9. Any reported adverse effects or toxicity of clotting factor concentrates</h6> <p>There was no reported inhibitor development reported in six of the trials in this comparison (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p>Transient low‐titer anti‐FVIII inhibitory antibodies, which resolved before the end of the trial, was reported in one out of 58 participants in the PROPEL III trial, in the arm targeting trough levels of 8% to 12% (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> <p>The Valentino trial reported (at 32 weeks follow‐up) no differences in total treatment‐emergent adverse events, MD 1.00 (95% CI 0.54, 1.84) (<a href="./references#CD014201-fig-0013" title="">Analysis 1.11</a>) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p>Three trials did not report the rate of adverse events by treatment groups (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). However, in the LEOPOLD II trial, there were three reported treatment‐related adverse events, but no details regarding the type of event or group were given (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> <p>In the 2012 Valentino trial that compared standard prophylaxis to a PK‐tailored regimen, there was no difference in mean rates of adverse events between the two regimens at 12 months follow‐up, MD 0.27 (95% CI ‐0.44 to 0.98) (<a href="./references#CD014201-fig-0014" title="">Analysis 1.12</a>) (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). </p> <p>Serious and non‐serious adverse events were reported in the PROPEL III trial. However, two out of 101 and two out of 103 of these events were estimated to be treatment‐related in the arm targeting 1% to 3% and 8% to 12% respectively (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). In the arm targeting trough levels of 1% to 3%, no serious adverse event was treatment‐related, and in the arm targeting trough levels of 8% to 12%, one serious adverse event was estimated to be treatment‐related. </p> <p>We assessed the certainty of the evidence as very low. </p> </section> </section> </section> <section id="CD014201-sec-0077"> <h4 class="title">Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation </h4> <p>The certainty of the evidence has been graded for those outcomes included in the summary of findings table (<a href="./full#CD014201-tbl-0002">summary of findings Table 2</a>). For the definitions of these gradings, please refer to the summary of findings tables. </p> <p>One trial was included in this comparison (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). </p> <p>The 2012 LipLong trial (143 participants) compared a standard prophylaxis dose to a new investigational drug, pegylated liposome FVIII formulation (BAY 79‐4980), given once‐weekly (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>); 73 participants were randomised to the prophylaxis group and 70 to the BAY79‐4980 group. Four randomised participants did not receive the intervention drugs, leaving 139 participants (n = 67 in BAY 79‐4980 and n = 72 in the prophylaxis group) for analysis. The sponsor halted the trial prematurely based on the recommendations of the data safety and monitoring board, indicating that the primary and secondary endpoints of non‐inferiority with prophylaxis with rFVIII‐FS three times/week would not be met. No safety issues were cited as the reason for early termination. The efficacy outcomes of this trial were reported as a per‐protocol analysis set. </p> <section id="CD014201-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD014201-sec-0079"> <h6 class="title">1. Number of joint bleeding episodes or joint bleeding frequency</h6> <p>This outcome was reported in terms of annualised bleeding rates. This comparison showed fewer joint bleeding with the standard prophylaxis regimen compared to the investigational drug BAY 79‐4980, MD ‐7.20 (95% CI ‐11.01 to ‐3.39) (low‐certainty evidence) (<a href="./references#CD014201-fig-0015" title="">Analysis 2.1</a>) (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). </p> </section> <section id="CD014201-sec-0080"> <h6 class="title">2. Orthopedic joint score or clinical joint function</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0081"> <h6 class="title">3. QoL on validated scales</h6> <p>This outcome was not reported.</p> </section> </section> <section id="CD014201-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD014201-sec-0083"> <h6 class="title">1. Number of total bleeding episodes or total bleeding frequency</h6> <p>This outcome was reported in terms of annualised bleeding rates. There was a statistically significant difference favouring the prophylaxis regimen compared to the investigational drug BAY 79‐4980, MD ‐9.20 (95% CI ‐13.07 to ‐5.33) (low‐certainty evidence) (<a href="./references#CD014201-fig-0016" title="">Analysis 2.2</a>) (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). </p> </section> <section id="CD014201-sec-0084"> <h6 class="title">2. Pain scores</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0085"> <h6 class="title">3. Radiologic joint score or radiologic measurements or descriptions of joint damage</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0086"> <h6 class="title">4. Clotting factor concentrate plasma levels</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0087"> <h6 class="title">5. Time loss to school or employment</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0088"> <h6 class="title">6. Integration into society</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0089"> <h6 class="title">7. Scores on scales recording feeling of well‐being and global functioning</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0090"> <h6 class="title">8. Economic data</h6> <p>This outcome was not reported.</p> </section> <section id="CD014201-sec-0091"> <h6 class="title">9. Any reported adverse effects or toxicity of clotting factor concentrates</h6> <p>One participant in the prophylaxis group reported three serious adverse events, which were deemed to be drug‐related (<a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). No specific information was given about the presence of adverse events in the BAY 70‐4980 group. No participant developed inhibitors to FVIII over the course of the trial. We judged the certainty of the evidence to be low. </p> </section> </section> </section> <section id="CD014201-sec-0092"> <h4 class="title">Prophylaxis regimen compared to on‐demand (episodic) treatment</h4> <p>The certainty of the evidence has been graded for those outcomes included in the summary of findings table (<a href="./full#CD014201-tbl-0003">summary of findings Table 3</a>). For the definitions of these gradings, please refer to the summary of findings tables. </p> <p>Four trials were reported on this comparison (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). In the Valentino 2012 trial, while comparing prophylaxis and on‐demand treatments, the comparison was not across the randomised allocation and hence was not included in the following analyses (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). Of note, this trial found that any type of secondary prophylaxis (standard versus PK‐adjusted) was significantly protective for total bleeding and joint bleeding when compared to episodic treatment (P &lt; 0.0001). Also, this trial reported a significant improvement in QoL for the bodily pain (4.1, P = 0.0007) and physical component score (PCS) (3.6, P = 0.0002) domains as measured on the SF36v1 scale for prophylaxis (any type) versus on‐demand treatment (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). </p> <section id="CD014201-sec-0093"> <h5 class="title">Primary outcomes</h5> <section id="CD014201-sec-0094"> <h6 class="title">1. Number of joint bleeding episodes or joint bleeding frequency</h6> <p>All trials reported this outcome.</p> <p>Data from two combined trials suggest that the use of a prophylaxis regimen significantly decreases the number of joint bleeds when compared to on‐demand treatments, MD ‐30.34 (95% CI ‐46.95 to ‐13.73) (low‐certainty evidence) (<a href="./references#CD014201-fig-0017" title="">Analysis 3.1</a>) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Considerable heterogeneity was seen in this analysis (I<sup>2</sup> = 87%). The data from the A‐LONG trial suggest the same effect; however, these data were reported with medians, hence could not be included in the above analysis (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>). </p> </section> <section id="CD014201-sec-0095"> <h6 class="title">2. Orthopedic joint score or clinical joint function</h6> <p>The three‐year follow‐up of the SPINART trial measured the joint function using the Colorado Joint Assessment Scale (CAJAS) (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). The CAJAS provides a score taking into account nine items for knee and ankles and seven for elbows. Data from the original report showed a mild improvement in joint health in the prophylaxis group at year three, least square (LS) mean ‐0.31 (95% CI ‐0.79 to 0.18), while the on‐demand group experienced a mild deterioration, LS mean 0.63 (95% CI 0.08 to 1.18). Comparing the two regimens, the estimated change difference was 0.94 points (95% CI 0.23 to 1.65) in favour of the prophylaxis regimen (<a href="./references#CD014201-fig-0018" title="">Analysis 3.2</a>) (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). </p> </section> <section id="CD014201-sec-0096"> <h6 class="title">3. QoL on validated scales</h6> <p>The HAEMO‐QoL‐A and EQ‐5D questionnaires were used in the SPINART trial (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Questionnaires were completed at baseline, six months, years one, two and three. LS mean changes in HAEMO‐QoL‐A score from baseline to year three showed an improvement in the prophylaxis group and a deterioration in the on‐demand group resulting in a 9.98 point (95% CI 3.42 to 16.54) difference in favour of prophylaxis. Similarly, the EQ‐5D showed improved HRQoL in the prophylaxis group with a mean (SD) change of 0.06 (0.15), whereas almost no change was seen for the on‐demand group with a mean (SD) change of ‐0.01 (0.16) in utility index score from baseline to year three. </p> </section> </section> <section id="CD014201-sec-0097"> <h5 class="title">Secondary outcomes</h5> <section id="CD014201-sec-0098"> <h6 class="title">1. Number of total bleeding episodes or total bleeding frequency</h6> <p>Data from two combined trials suggest that the use of a prophylaxis regimen is significantly more protective than on‐demand treatment when preventing bleeding episodes, MD ‐40.24 (95% CI ‐64.04 to ‐16.44) (low‐certainty evidence) (<a href="./references#CD014201-fig-0019" title="">Analysis 3.3</a>) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Considerable heterogeneity was also seen in this analysis (I<sup>2</sup> = 93%). Total bleeding rates in the A‐LONG trial also suggest a similar effect and were also not included in this analysis as data were reported as medians (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>). </p> </section> <section id="CD014201-sec-0099"> <h6 class="title">2. Pain scores</h6> <p>The SPINART trial reports the results for the Short‐Form McGill Pain Questionnaire total score, determined at baseline and years one, two and three (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). At three years, the participants enrolled in the prophylaxis group reported a 50% decrease in pain for the previous four weeks, mean 17.2 (SD 22.9), whereas on‐demand participants reported no change, mean 0.0 (SD 25.1), resulting in a MD of ‐ 17.20 (95% CI ‐27.48 to ‐6.92) in total score in favour of prophylaxis (<a href="./references#CD014201-fig-0020" title="">Analysis 3.4</a>) (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). </p> </section> <section id="CD014201-sec-0100"> <h6 class="title">3. Radiologic joint score or radiologic measurements or descriptions of joint damage</h6> <p>The SPINART trial used the 45‐item eMRI scale, previously validated with baseline data. Six index joints (knees, ankles, and elbows) were evaluated and each MRI was independently scored by three radiologists that were blinded to treatment allocation (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Overall, the results at year three indicated detectable deteriorations on eMRI from baseline in both the prophylaxis group and the on‐demand group (mean (SD) 0.75 (1.59) and 0.92 (SD 1.15) respectively) and a total MD ‐18.39 (95% CI ‐21.55 to 15.23) (<a href="./references#CD014201-fig-0021" title="">Analysis 3.5</a>) <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). However, LS mean changes of ‐0.71 between the two regimens were not considered significantly different. </p> </section> <section id="CD014201-sec-0101"> <h6 class="title">4. Clotting factor concentrate plasma levels</h6> <p>This outcome was not reported in any of the included trials for this comparison.</p> </section> <section id="CD014201-sec-0102"> <h6 class="title">5. Time loss to school or employment</h6> <p>One trial reported the time spent under medical care (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). In this trial, more than three hours under medical care were noted as one day. The authors reported that children on prophylaxis spent significantly less time confined to bed. </p> </section> <section id="CD014201-sec-0103"> <h6 class="title">6. Integration into society</h6> <p>This outcome was not reported in any of the included trials for this comparison.</p> </section> <section id="CD014201-sec-0104"> <h6 class="title">7. Scores on scales recording feeling of well‐being and global functioning</h6> <p>This outcome was not reported in any of the included trials for this comparison.</p> </section> <section id="CD014201-sec-0105"> <h6 class="title">8. Economic data</h6> <p>This outcome was not reported in any of the included trials for this comparison.</p> </section> <section id="CD014201-sec-0106"> <h6 class="title">9. Any reported adverse effects or toxicity of clotting factor concentrates</h6> <p>When considering the number of individuals who experienced an adverse event, over two trials, more adverse events were reported in the participants on prophylaxis compared to those on on‐demand therapy,  RR 1.71 (95% CI 1.24 to 2.37)  (<a href="./references#CD014201-fig-0022" title="">Analysis 3.6</a>) (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). The distribution of adverse events across groups was not given in the LEOPOLD II trial, and hence it was not included in the above analysis. Of note, there were three reported treatment‐related adverse events, but no participant developed an inhibitor during the course of treatment (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). In the 1976 Aronstam trial, one participant developed antigen‐negative hepatitis and was removed from the remaining duration of the trial (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014201-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014201-sec-0107"></div> <section id="CD014201-sec-0108"> <h3 class="title" id="CD014201-sec-0108">Summary of main results</h3> <p>This Cochrane Review included 10 trials with a total of 608 people with severe or moderate haemophilia A (n = 548) or B (n = 60), who had been previously treated for their disease. These trials yielded two different comparisons: </p> <p> <ol id="CD014201-list-0015"> <li> <p>comparison between two prophylaxis regimens; including prophylaxis with a standard, commercial rFVIII and a new investigational drug; and </p> </li> <li> <p>standard prophylaxis versus on‐demand treatment.</p> </li> </ol> </p> <p>Due to differences in treatment schedules and reporting methods, we were only able to aggregate data for our primary outcomes in one of the comparisons. </p> <p>The data included in the review from the individual studies and the aggregated data suggest that secondary prophylaxis may be superior to on‐demand treatment for preventing both joint bleeding incidents and overall bleeding (low‐certainty evidence). Prophylaxis may also improve joint function, pain and QoL (low‐certainty evidence). However, it seems that the regimens tested were not effective in halting or reversing the progression of arthropathy once structural joint damage has occurred. In fact, no detectable improvement, as assessed by MRI, of articular damage could be found at the three‐year observation time‐point in the SPINART trial. </p> <p>When considering the comparison between two prophylaxis regimens, no individual prophylactic treatment schedule investigated proved to be superior at preventing total bleeding events in people in haemophilia A. Finally, standard prophylaxis may be more effective at preventing joint and total bleeding events than the experimental drug BAY 79‐4980 (low‐certainty evidence). Individuals with hemophilia B were included in two trials (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). The Morfini trial showed that a twice‐weekly regimen of prophylaxis may be superior to a once‐weekly regimen in decreasing total bleeding incidence, but these results should be interpreted cautiously given the small number of participants, the extremely low dose used and the fact that none of the participants were blinded to their treatment allocation (low‐certainty evidence). The results of the Valentino 2014 trial did not establish a superior prophylaxis regimen; however, this trial did show that prophylaxis at any dosing schedule was superior to on‐demand treatment to prevent spontaneous bleeds and joint bleeding incidence (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). When considering these data, it must be kept in mind that the bleeding data were aggregated for only 16 weeks, and the annualized bleeding rates were extrapolated from this time period. </p> <p>Regarding the incidence of adverse events, when considering the comparison of prophylaxis versus on‐demand treatment, the moderate‐certainty evidence showed that on‐demand treatment probably reduces the incidence of adverse events (131 participants, two trials) (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). However, all individuals with a past history of an inhibitor were excluded from the trials and so information for this group is not available. </p> <p>Of note, in the LEOPOLD II 2015 trial, participants were crossed over between groups to receive factor that was labelled in different ways (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). Each participant received six months of the trial drug labelled with a chromogenic substrate assay per European Pharmacopoeia, followed by six months of the trial drug labelled using a correction factor to simulate the results obtained with the one‐stage assay. Because of this, trial authors report that participants likely received approximately 20% to 25% higher factor concentrate product in the time period when received FVIII based on the one‐stage adjusted labelling method. Since all participants in the trial were given both the factor concentrate based on the two labelling methods, all participants were subject to the fluctuation in factor concentrate. Hence, we did not deem it necessary to alter our analyses to accommodate for the use of a substrate assay in this trial (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> <p>Since one of the goals of initiating secondary prophylaxis is to prevent further deterioration of target joints, we decided to use joint bleeds, rather than total bleeds, as our primary outcome. However, interestingly this outcome was infrequently reported separately from total bleeding events. In addition, only two trials assessed joint function. </p> <p>One limitation of this review was our inability to aggregate data for most of our outcomes. There were two main reasons for which we were unable to aggregate data: </p> <p> <ol id="CD014201-list-0016"> <li> <p>diversity in participant characteristics and treatment regimens; and</p> </li> <li> <p>diversity in reporting methods.</p> </li> </ol> </p> <p>We hoped to be able to combine data from trials comparing different secondary prophylaxis regimens in order to give a more powerful estimate of the use of secondary prophylaxis. However, we found that the differences in participants and treatment arms between trials were too great to generate a reliable aggregate result. Many of the outcomes were reported as medians with ranges, while others were reported as means. Medians are often used when data are skewed, as might be the case with bleeding events, where individuals with a very high or very low number of bleeding events may pull an estimate in one direction. Often, a median can be used to approximate to mean values, but since our sample sizes were comparatively small, we decided against using this approach, as this may not have been an accurate approximation. We hope that as haemophilia treatment becomes increasingly optimised, and based on large randomised trials, the barriers that precluded us from aggregating data in this review will no longer exist. </p> <p> </p> </section> <section id="CD014201-sec-0109"> <h3 class="title" id="CD014201-sec-0109">Overall completeness and applicability of evidence</h3> <p>We conducted this review to investigate the effectiveness of clotting factor concentrate prophylaxis in managing previously‐treated individuals with haemophilia A or B. In this Cochrane Review, we included only RCTs, and the primary outcome for this review, joint bleeding events or joint bleeding frequency, was reported in seven out of the 10 trials. Overall bleeding events or overall bleeding frequency were reported in all 10 trials. Other secondary outcomes such as clinical joint function and radiologic measurements were reported in two trials (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Two trials also reported conducting QoL assessments (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>) and one trial reported the results of pain assessment (<a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). Participants included people with haemophilia A and B and mostly characterised by FVIII or FIX levels &lt; 1% of normal. Two trials included people with severe or moderately severe (factor levels ≤ 2%) haemophilia A or B. The evidence summarised in this review is applicable to individuals with moderate‐severe to severe hemophilia A and B on secondary prophylaxis. </p> </section> <section id="CD014201-sec-0110"> <h3 class="title" id="CD014201-sec-0110">Quality of the evidence</h3> <p>Overall, we found the included trials to be at low risk or unclear risk of bias for most domains. In particular, while all trial reports indicated that the trial was randomised, only four of the 10 included trials indicated the method used for random sequence generation (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>), with only two were assessed as having a low risk of bias for the domain (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). When considering the method for allocation concealment four trials were judged to be at low risk of bias for this domain (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). The remaining six trials had an unclear risk of bias (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>; (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). Also, three of the included trials used an appropriate method to blind participants and personnel to minimize performance bias (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>, <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>, <a href="./references#CD014201-bbs2-0005" title="Di MinnoG , CerboneAM , CoppolaA , CiminoE , Di CapuaM , PamparanaF , et al. Longer-acting factor VIII to overcome limitations in haemophilia management: The PEGylated liposomes formulation issue. Haemophilia2010;16 Suppl 1:2-6. [CFGD REGISTER: HA104c] LalezariS , CoppolaA , LinJ , EnriquezMM , Tseneklidou-StoeterD , PowellJ , et al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia2014;20(3):354-61. [CFGD REGISTER: HA104f] LalezariS , CoppolaA , LinJ , EnriquezMM . Subgroup analyses of annualized number of bleeds with three-times-per-week prophylaxis with rFVIII-FS. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:373. [ABSTRACT NO: P-TU-204] [CFGD REGISTER: HA104g] LalezariS , MartinowitzU , WindygaJ , EnriquezMM , DelesenH , SchwartzL , et al. Correlation between endogenous VWF: ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia2014;20(1):e15-22. [CFGD REGISTER: HA104e] MartinowitzU , WindygaJ , PowellJ , Maas EnriquezM , ScharrerI . Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels form a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-061] [CFGD REGISTER: HA104a] PowellJ , IngerslevJ , EnriquezMM , MartinowitzU . Efficacy and safety of prophylaxis with once-weekly bay 79-4980 vs. three-times-weekly rFVIII-FS: a randomized, active-controlled, double-blind study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:726. [ABSTRACT NO: O-TH-016] [CFGD REGISTER: HA104h] PowellJ , MartinowitzU , WindygaJ , Di MinnoG ,  HellmannA ,  PabingerI , et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients: a randomised, active-controlled, double-blind study. Blood Coagulation, Fibrinolysis and Cellular Haemostasis2012;108:913-22. [CFGD REGISTER: HA104d] SchaferK , Tseneklidou-StoeterD , NelsonL , Maas EnriquezM . Experience with electronic patient diaries in a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-062] [CFGD REGISTER: HA104b] ">LipLong 2012</a>). The remaining seven trials were open‐label. Regarding the possibility of reporting bias, all included trials were judged to have a low risk of bias for this domain. </p> <p>Overall, the certainty of the evidence was considered to be low because of different types of bias that could have altered the effect. In the comparison of two prophylaxis regimens, the certainty of the evidence was downgraded twice due to performance and detection bias as included studies were open‐label and due to incomplete outcome data. The certainty of the evidence was also downgraded due to high levels of heterogeneity across trials In the comparison of prophylaxis and on‐demand regimens. Future research might have an important role in changing our confidence in the estimate of effect. </p> </section> <section id="CD014201-sec-0111"> <h3 class="title" id="CD014201-sec-0111">Potential biases in the review process</h3> <p>We attempted to minimise the possibility of bias in the review process and all the authors had access to all the data and critically reviewed the manuscript. Our search strategy has been as inclusive as possible, and no specific restrictions were placed on the language or date of publication when searching databases. It is unlikely that potentially relevant trials were missed, also considering that in addition to the search of the electronic databases the bibliographic references of all retrieved trials and reviews were assessed for additional reports of potential interest. We also handsearched the proceedings of the International Society for Thrombosis and Haemostasis bi‐annual meeting and proceedings of the European Association for Haemophilia and Allied Disorders. </p> </section> <section id="CD014201-sec-0112"> <h3 class="title" id="CD014201-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>Overall the conclusions of this review are in substantial agreement with the recent literature assessing the importance of secondary prophylaxis in haemophilia (<a href="./references#CD014201-bbs2-0090" title="NugentD , O'MahonyB , DolanG , International Haemophilia Access Strategy Council. Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia. Haemophilia2018;24(5):755-65.">Haemophilia 2018</a>). It is also interesting to consider that consistent results were obtained in a 2015 non‐randomised study investigating the effects of long‐term late secondary prophylaxis compared with on‐demand treatment in haemophilia (<a href="./references#CD014201-bbs2-0100" title="TagliaferriA , FeolaG , MolinariAC , SantoroC , RivoltaGF , CultreraDB , et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thrombosis and Haemostasis2015;114(1):35-45.">POTTER 2015</a>). Results from this study support the efficacy of late secondary and tertiary prophylaxis, which ultimately significantly decreased the frequency of all bleeding episodes, including joint bleeds, and improved joint status. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014201-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014201-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 1: Joint bleeds per year" data-id="CD014201-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 1: Joint bleeds per year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 2: Joint bleeds per year (2)" data-id="CD014201-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 2: Joint bleeds per year (2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 3: Spontaneous joint bleeds" data-id="CD014201-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 3: Spontaneous joint bleeds </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 4: Joint bleeds per year (3)" data-id="CD014201-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 4: Joint bleeds per year (3) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 5: Total bleeds per year" data-id="CD014201-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 5: Total bleeds per year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 6: Overall bleeding frequency (bleeds per 100 days)" data-id="CD014201-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 6: Overall bleeding frequency (bleeds per 100 days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 7: Annualised bleeding rates" data-id="CD014201-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 7: Annualised bleeding rates </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 8: Total bleeding frequency (HB)" data-id="CD014201-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 8: Total bleeding frequency (HB) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 9: Overall bleeding frequency" data-id="CD014201-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 9: Overall bleeding frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 10: Total bleeds per year (2)" data-id="CD014201-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 10: Total bleeds per year (2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 11: Total treatment emergent adverse event" data-id="CD014201-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 11: Total treatment emergent adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison between two prophylaxis regimens, Outcome 12: Rate of adverse events" data-id="CD014201-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Comparison between two prophylaxis regimens, Outcome 12: Rate of adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard prophylaxis versus investigational drug, Outcome 1: Annualised joint bleeding rate" data-id="CD014201-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Standard prophylaxis versus investigational drug, Outcome 1: Annualised joint bleeding rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard prophylaxis versus investigational drug, Outcome 2: Annualised total bleeding rate" data-id="CD014201-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Standard prophylaxis versus investigational drug, Outcome 2: Annualised total bleeding rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 1: Mean total joint bleeds per year" data-id="CD014201-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 1: Mean total joint bleeds per year </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 2: Mean change in joint health scores (CAJAS)" data-id="CD014201-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 2: Mean change in joint health scores (CAJAS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 3: Mean total bleeds per year" data-id="CD014201-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 3: Mean total bleeds per year</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 4: Pain scores" data-id="CD014201-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 4: Pain scores</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 5: Radiologic measurements of joint damage (deterioration shown in eMRI)" data-id="CD014201-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 5: Radiologic measurements of joint damage (deterioration shown in eMRI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014201-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/urn:x-wiley:14651858:media:CD014201:CD014201-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Prophylaxis versus on‐demand, Outcome 6: Participants with adverse events" data-id="CD014201-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_t/tCD014201-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Prophylaxis versus on‐demand, Outcome 6: Participants with adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014201/media/CDSR/CD014201/image_n/nCD014201-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014201-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison of two prophylaxis regimens</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis regimen compared with another prophylaxis regimen for previously treated individuals with haemophilia A or B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children or adults with hemophilia A or B </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: secondary prophylaxis </p> <p><b>Comparison</b>: secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of joint bleeding episodes per year (AJBR) </p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No difference was seen between prophylaxis regimens in any of the studies. Thrice‐weekly higher dose prophylaxis regimen compared to a twice‐weekly lower dose regimen, MD ‐1.70 (95% CI ‐5.06 to 1.66) (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>).  </p> <p> </p> <p>PK‐guided prophylaxis targeting trough levels of 8% to 12% compared to targeting trough levels of 1% to 3%, MD ‐1.50 (95% CI ‐3.54 to 0.54) (n = 115 participants) (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> <p> </p> <p>Low frequency prophylaxis (100 IU / kg once a week) compared to standard frequency regimen (50 IU / kg twice a week, MD of 1.70 (95% CI ‐1.09 to 4.49) (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219 participants</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to combine results in a meta‐analysis due to the different prophylaxis regimens used in each trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of total bleeds per year (ABR)</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>There was no difference in total number of bleeds between prophylactic regimens in five trials (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> <p> </p> <p>A twice‐a‐week regimen (7.5 IU/kg) was favoured over a once‐a‐week regimen (15 IU/kg), MD 11.20 (5.81 to 16.59) (<a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>) and a prophylaxis group with dosing producing at least 0.25 IU/mL of factor VIII showed a significant reduction in overall bleeding frequency compared to a dosing regimen producing at least 0.01IU/mL once weekly, MD 3.44 (95% CI 2.42 to 4.46) (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310 participants</p> <p>(7 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to heterogeneity of intervention and design, none of the trials we were unable to combine data from any of the trials (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐related adverse events</p> <p> </p> <p>Follow‐up: 32 weeks to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>One trial reported no difference in total treatment‐emergent adverse events, MD 1.00 (95% CI 0.54 to 1.84) at 32 weeks (<a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). A further trial reported no difference between treatment regimens in mean rates of adverse events (<a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>). </p> <p>In the study targeting different trough levels, no serious adverse event was treatment‐related in the arm targeting trough levels of of 1% to ‐3%, and in the arm targeting trough levels of 8% to ‐12%, one serious adverse event was estimated to be treatment‐related (<a href="./references#CD014201-bbs2-0007" title="CollinsP , WindygaJ , EscobarM , IbrahimHM , LamJCM , TangadaSD , et al. Efficacy and target joint resolution with pharmacokinetic-guided rurioctocog alfa pegol prophylaxis targeting two factor VIII trough levels in patients with severe hemophilia A: post-hoc analysis of the phase 3 propel trial. Research and Practice in Thrombosis and Haemostasis2020;4 Suppl 1:455. [CFGD REGISTER: HA137j] Escuriola-EttingshausenC , KlamrothR , EscobarM , MullinsES , StasyshynO , TangadaS , et al. Personalizing prophylaxis with rurioctocog alfa pegol in previously treated patients with severe hemophilia A: outcomes from the phase 3B continuation and phase 3 propel studies. Research and Practice in Thrombosis and Haemostasis2020;4(Suppl 1):453-4. [CFGD REGISTER: HA137i] HorlingFM , AllacherP , KoppensteinerH , EnglW , ScheiflingerF , AbbuehlBE , et al. Immunogenicity of BAX 855 in previously treated patients with congenital severe hemophilia A. Blood2016;128(22):2594. [CFGD REGISTER: HA137a] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. PK-guided rurioctocog alfa pegol prophylaxis in patients with severe hemophilia A targeting two FVIII trough levels: results from the phase 3 propel study. Research and practice in thrombosis and haemostasis2019;3:106-7. [CFGD REGISTER: HA137e] KlamrothR , WindygaJ , RadulescuV , CollinsP , StasyshynO , IbrahimHM , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PK-guided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (propel study). Haemophilia2019;25:162. [CFGD REGISTER: HA137d] KlamrothR , WindygaJ , RadulescuV , CollinsPW , StasyshynO , IbrahimHM , et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood2021;137(13):1818-27. [CFGD REGISTER: HA137h] [DOI: 10.1182/blood.2020005673]NCT02585960. BAX 855 pk-guided dosing. clinicaltrials.gov/show/nct02585960 (first posted 26 October 2015). [CFGD REGISTER: HA137b] RadulescuV , KlamrothR , WindygaJ , CollinsP , StasyshynO , Mohd IbrahimH , et al. Results from a phase 3, randomized, multicenter study of Rurioctocog Alfa Pegol PK-guided prophylaxis targeting two FVIII trough levels in patients with severe hemophilia A (PROPEL Study). Haemophilia2019;25:57-8. [CFGD REGISTER: HA137f] RobertK , JerzyW , VladR , PeterC , OleksandraS , Mohd HishamshahI , et al. Results from a phase 3, randomized, multicenter study of rurioctocog alfa pegol PKGuided prophylaxis targeting 2 FVIII trough levels in patients with severe hemophilia A (Propel Study). Hamostaseologie2019;39(S1):S1-92. [CFGD REGISTER: HA137c] WindygaJ , CollinsP , Escuriola-EttingshausenC , EscobarM , ShapiroS , ZulfikarB , et al. Rurioctocog alfa pegol PK-guided prophylaxis targeting two FVIII trough levels in severe hemophilia a patients (PROPEL phase 3 study): impact of patient FVIII half-life on consumption and efficacy outcomes. Haemophilia2020;26:25. [CFGD REGISTER: HA137g] ">PROPEL III 2020</a>). </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 </p> <p>participants</p> <p>(3 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three trials did not report the rate of adverse events by treatment groups (<a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>). The LEOPOLD II trial reported three treatment related  adverse events but gave no further detail (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). </p> <p>There was no reported inhibitor development reported in six of the trials in this comparison (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>; <a href="./references#CD014201-bbs2-0003" title="AronstamA , KirkPJ , McHardyJ , Culver-JamesJW , McLellanDS , TurkP , et al. Twice weekly prophylactic therapy in haemophilia A. Journal of Clinical Pathology1977;30(1):65-7. [CENTRAL: CN-00462731] [CFGD REGISTER: HA80] ">Aronstam 1977</a>; <a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>; <a href="./references#CD014201-bbs2-0006" title="MorfiniM , MannucciPM , MarianiG , PanicucciF , PetrucciF , BaicchiU , et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology1976;16(1):41-7. [CENTRAL: CN-00013490] [CFGD REGISTER: HB8] [EMBASE: 1977017603] [PMID: 1251139]">Morfini 1976</a>; <a href="./references#CD014201-bbs2-0009" title="ChowdaryP , FischerK , CollinsPW , CotterillA , KonkleBA , BlanchetteV , et al. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia a initiated on tertiary prophylaxis. Thrombosis and Haemostasis2020;120(5):728-36. [CFGD REGISTER: HA107g] NCT00243386. Prophylaxis study of recombinant factor VIII manufactured protein-free (rahf-pfm) in patients with hemophilia a. clinicaltrials.gov/show/NCT00243386 2005 (first posted 24 October 2005). [CFGD REGISTER: HA107f] QuonDV , ShapiroAD , SantagostinoE , ValentinoLA . Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:1081. [ABSTRACT NO: PO 160] [CFGD REGISTER: HA107c] ShapiroAD , SantagostinoE , EpsteinJD , SchrothP , WongWY . Significant improvement in health-related quality of life with prophylaxis in severe hemophilia A: results from the rAHF-PFM randomized, controlled prophylaxis study. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:827. [ABSTRACT NO: P-TH-184] [CFGD REGISTER: HA107d] ValentinoLA , MamonovV , HellmannA , QuonDV , ChybickaA , SchrothP , et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. Journal of Thrombosis and Haemostasis2012;10:359-67. [CFGD REGISTER: HA107a] ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CENTRAL: CN-01002062] [EMBASE: 53024411] [HA107b]ValentinoLA , ReyesCM , EwensteinB , Guzman-BecerraN , WongWY , Schoenig-DiesingC , et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia2014;20(5):630-8. [CFGD REGISTER: HA107e] ">Valentino 2012</a>; <a href="./references#CD014201-bbs2-0010" title="Korth-BradleyJ , SmithL , FuimanJ , RendoP . Pharmacokinetic (PK) and clinical data support for effectiveness of once-weekly recombinant coagulation factor IX (RFIX) dosing for prophylaxis in patients with moderately severe or severe hemophilia B. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:322. [ABSTRACT NO: PO167-MON] [CFGD REGISTER: HB21g] RendoP , Barrette-GrischowMK , SmithL , Korth-BradleyJM , CharnigoR , ShaferFE . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX ≤2%) hemophilia B patients. Blood2012;120(21). [ABSTRACT NO: 4628] [CFGD REGISTER: HB21c] RendoP , SmithL , Korth-BradleyJ , CharnigoR , ShaferF . Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-fix) in moderately severe to severe (fix a‰¤ 2%) hemophilia B patients. Haemophilia2013;19 Suppl 2:20. [ABSTRACT NO: PO018] [CFGD REGISTER: HB21a] ShaferF , SmithL , VendettiN , RendoP , CarrM . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy. Haemophilia2014;20(3):349-53. [HB21e]ShaferFE , SmithL , VendettiN , RendoP , CarrME . Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with hemophilia b receiving on-demand therapy. Blood2012;120(21). [ABSTRACT NO: 1136] [CFGD REGISTER: HB21d] ValentinoLA , PlushchO , RusenL , AndreevaT , ElezovicI , CharnigoR , et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. Journal of thrombosis and haemostasis : JTH2011;9 Suppl 2:357. [ABSTRACT NO: P-TU-155] [CFGD REGISTER: HB21b] ValentinoLA , RusenL , ElezovicI , SmithLM , Korth-BradleyJM , RendoP . Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia2014;20(3):398–406. [CFGD REGISTER: HB21f] ">Valentino 2014</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>ABR</b> : annualised bleed rate; <b>AJBR</b> : annualised joint bleed rate; <b>CI</b> : confidence interval; <b>FIX</b> : factor IX; <b>RR</b> : risk ratio; <b>MD</b>: mean difference.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded twice due to risk of bias in the included trials, particularly across the domains of randomisation and allocation concealment. The trials were also considererd at high risk of bias due to lack of blinding <br/>b. Downgraded once due to imprecision as a result of small sample sizes. Although the total number of participants included in this outcome is 390, none of the studies could be combined and so we have based our assessment on the numbers in individual trials. The two trials that showed a difference between regimens included nine and 10 participants. </p> <p>c. Downgraded twice due to an unclear or high risk of bias across many of the domains with particular concern around randomisation procedures, allocation concealment and blinding. </p> <p>d. Downgraded once due to imprecision from small sample size and low event rates. Although the total number of participants is reasonable, none of the trials could be combined and so we have based our judgement on the numbers in the individual trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison of two prophylaxis regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014201-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis with standard clotting factor concentrate compared with pegylated liposome FVIII formulation for previously treated individuals with haemophilia A</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children or adults with hemophilia A </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: prophylaxis using investigational BAY 79‐4980 </p> <p><b>Comparison</b>: standard secondary prophylaxis </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis using investigational BAY 79‐4980</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AJBR</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of joint bleeding in the prophylaxis arm using investigational drug BAY 79‐4980 was 12.2. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of joint bleeding in the standard prophylaxis regimen (5.0), was 7.20 lower (11.01 lower to 3.39 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.20</p> <p>(‐11.01 to ‐3.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More participants withdrew consent in the investigational drug arm. The trial was prematurely discontinued by the sponsor based on the recommendation of an independent data and safety monitoring board. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABR</p> <p> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of total bleeds in the prophylaxis arm using investigational drug BAY 79‐4980 was 15. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of total bleeds in the standard prophylaxis regimen (5.8), was 9.20 lower (13.07 lower to 5.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.20</p> <p>(‐13.07 to ‐5.33 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More participants withdrew consent in the investigational drug arm. The trial was prematurely discontinued by the sponsor based on the recommendation of an independent data and safety monitoring board. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any reported adverse effects</p> <p> </p> <p>Follow‐up: 12 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No specific information was given about the presence/absence of adverse events in the BAY 70‐4980 group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>One participant in the prophylaxis group reported three serious adverse events, which were deemed to be drug related. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143 participants</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>ABR</b> : annualised bleed rate; <b>AJBR</b> : annualised joint bleed rate; <b>CI</b> : confidence interval; <b>MD</b>: mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low cerainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to high risk of bias due to attrition bias from incomplete outcome data.<br/>b. Downgraded once due to premature study discontinuation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prophylaxis with standard therapeutic factor concentrate compared to pegylated liposome FVIII formulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014201-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylaxis regimen versus on‐demand treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylaxis regimen compared with on‐demand treatment for previously treated individuals with haemophilia A or B</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with haemophilia A or B </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: secondary prophylaxis </p> <p><b>Comparison</b>: on‐demand treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>On‐demand treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Prophylaxis regimen</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of joint bleeding episodes or joint bleeding frequency</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of joint bleeding episodes in the on‐demand treatment group was 34</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of joint bleeding episodes in the prophylaxis regimen group was 30.34 lower (46.95 lower to 13.73 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐30.34 (‐46.95 to ‐13.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The data from the A‐LONG trial suggests the same; however, these data were reported with medians, hence could not be included in the analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of total bleeds per year or bleeding frequency</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of total bleeds in the on‐demand treatment group was 44</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean number of total bleeds in the prophylaxis regimen group was 40.24 lower (64.04 lower to 16.44 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐40.24 (‐64.04 to ‐16.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The data from the A‐LONG trial suggests the same effect; however, these data were reported with medians, hence could not be included in the analysis (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>). </p> <p>When comparing the overall bleeding frequency in 9 participants in the Aronstam cross‐over trial, there was a significant reduction in the overall bleeding frequency in the prophylaxis group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any reported adverse events</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>415 per 1000 (27 per 65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>712 per 1000 (47 per 66)</p> <p>The number of participants with adverse events in the prophylaxis regimen group was 1.71 times higher (1.24 times higher to 2.37 times higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.71</p> <p>(1.24 to 2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The 2 trials were open‐label trials with unclear risk of bias for randomised sequence generation (<a href="./references#CD014201-bbs2-0001" title="KonkleB , PasiK , YoungG , RechtM , QuonD , TsaoE , et al. Long-term efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) prophylaxis in adults, adolescents, and children with severe hemophilia A: longitudinal analysis of A-LONG and ASPIRE studies. Haemophilia2017;23 Suppl 3:21. [CENTRAL: CN-01602316] [CFGD REGISTER: HA114f] KulkarniR , RagniMV , BakerRI , PasiJ , Manco-JohnsonMJ , PottsJ , et al. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor VIII Fc fusion protein in patients with severe hemophilia A. Haemophilia2014;20 Suppl 3:94. [CFGD REGISTER: HA114b] MahlanguJ , PowellJS , RagniMV , ChowdaryP , JosephsonNC , PabingerI , et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood2014;123(3):317-25. [CFGD REGISTER: HA114a] MahlanguJN , RagniM , GuptaN , RangarajanS , KlamrothR , OldenburgJ , et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis2016;116(1):1-8. [CENTRAL: CN-01414922] [CFGD REGISTER: HA114e / HA106b] [PMID: 26962852]ShapiroAD , RagniMV , KulkarniR , OldenbergJ , SrivastavaA , QuonDV , et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of thrombosis and haemostasis : JTH2014;12(11):1788-800. [CFGD REGISTER: HA114c] WyrwichKW , KrishnanS , AugusteP , PoonJL , vonMaltzahnR , YuR , et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia2016;22(6):866-72. [CENTRAL: CN-01262866] [CFGD REGISTER: HA114d] [PMID: 27385432]">A‐LONG 2014</a>; <a href="./references#CD014201-bbs2-0008" title="EUCTR2008-000985-21-BG. Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared to that of episodic treatment. (SPINART) - SPINART]. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-000985-21-BG (date of registration 4 February 2008). [CENTRAL: CN-01847483] [CFGD REGISTER: HA105r] FunkS , LundinB , HongW . Spinart 3-year analyses: patient- and joint-level changes in colorado adult joint assessment scale and magnetic resonance imaging scores with Bayer's sucrose-formulated recombinant factor VIII in adolescents and adults. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:244. [ABSTRACT NO: OR388] [CFGD REGISTER: HA105j] HongW , RaunigD , FunkS . 3-year joint outcomes in the SPINART trial: results using the Colorado adult joint assessment scale. Haemophilia2014;20 Suppl 3:63-4. [CFGD REGISTER: HA105f] HongW , RaunigD , FunkS . Joint outcome evaluation by magnetic resonance imaging: results at the 3-year evaluation in the SPINART study. Haemophilia2014;20 Suppl 3:63. [CFGD REGISTER: HA105e] HongW , RaunigD , LundinB . SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data. Haemophilia2016;22(6):e519-26. [CENTRAL: CN-01289866] [CFGD REGISTER: HA105m] [EMBASE: 613346343] [PMID: 27642172]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of secondary prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2012;18(5):830-1. [CENTRAL: CN-01027887] [CFGD REGISTER: HA105n] [EMBASE: 71024222]KemptonC , ValluriS , RedingM , LissitchkovT , GoranovS , GerchevaL , et al. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A. Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO: PO-WE-058] [CFGD REGISTER: HA105a] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. 3-year analyses from spinart: Patient-and joint-level changes in magnetic resonance imaging scores with bayer's sucrose-formulated recombinant factor VIII (RFVIIIFS) in adolescents and adults previously treated on demand. Haemophilia2015;21:40-1. [CFGD REGISTER: HA105l] LundinB , HongW , RaunigD , EngelenS , PeterfyC , WerkM , et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart Study. In: 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California. 2014. [ABSTRACT NO: 2854] [CFGD REGISTER: HA105h] Manco‐JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Corrigendum to Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2014;12(1):119-22. [CENTRAL: CN-00980287] [CFGD REGISTER: HA105o] [EMBASE: 372087709]Manco-JohnsonM , KemptonCL , RedingMT , GoranovS , GerchevaL , RusenL , et al. 3-year results from SPINART: prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII. Haemophilia2014;20 Suppl 3:96. [CFGD REGISTER: HA105d] Manco-JohnsonMJ , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). Journal of Thrombosis and Haemostasis2013;11(16):1119-27. [CFGD REGISTER: HA105c] Manco-JohnsonMJ , LundinB , FunkS , PeterfyC , RaunigD , WerkM , et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. Journal of Thrombosis and Haemostasis2017;15(11):2115-24. [CFGD REGISTER: HA105p] NCT00623480. Trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects compared to that of episodic treatment [Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rfviii therapy in severe hemophilia a adult and/or adolescent subjects, AS applicable, compared to that of episodic treatment]. clinicaltrials.gov/show/NCT00623480 (first posted 26 February 2008). [CENTRAL: CN-01517226] [CFGD REGISTER: HA105q] PocoskiJ , HumphriesTJ , HongW . Spinart 3-year data: Patient-reported benefits of adult prophylaxis vs on-demand treatment with bayer's sucrose-formulated recombinant factor viii. Haemophilia2015;21:51-2. [CFGD REGISTER: HA105k] PocoskiJ , SilbermanC , HumphriesT , WalkerD , HongW . Spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor VIII. Journal of thrombosis and haemostasis : JTH2013;11 Suppl 2:20. [ABSTRACT NO: COA34] [CFGD REGISTER: HA105g] RedingMT , KemptonCL , FunkS , EngelenS , WalkerD , HongW . Spinart trial 3-year results with bayer's sucrose-formulated recombinant factor VIII: relationship between bleeding frequency and joint health in adults with severe hemophilia A using prophylaxis. Journal of thrombosis and haemostasis : JTH2015;13 Suppl 2:132. [ABSTRACT NO: OR101] [CFGD REGISTER: HA105i] ZarkovaAG , KemptonCL , RedingMT , LissitchkovT , GoranovS , GerchevaL , et al. Bleeding frequency subanalyses in a randomized controlled trial of prophylaxis vs on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A. Haemophilia2013;19 Suppl 2:28. [ABSTRACT NO: PO032] [CFGD REGISTER: HA105b] ">SPINART 2013</a>). </p> <p> </p> <p>The LEOPOLD II trial did not give the distribution of adverse events across groups, but there were 3 reported treatment‐related adverse events while no participant developed an inhibitor during the course of treatment (<a href="./references#CD014201-bbs2-0004" title="ChurchN , AyyagariR , PocoskiJ , SajeevG , SnehaK , DuEX , et al. Bleed occurrence after Bay 81-8973 injection and characteristics of patients who respond to prophylaxis: analyses from Leopold I and II. Haemophilia2016;22 Suppl 2:78-9. [CENTRAL: CN-01612491] [CFGD REGISTER: HA129j / HA111h] [EMBASE: 622470086]FujiiT , HanabusaH , ShimaM , MorinagaT , FukutakeK . Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product. International Journal of Hematology2017;105(3):280-6. [CENTRAL: CN-01215985] [CFGD REGISTER: HA111i] [PMID: 27832514]GarmannD , McLeayS , ShahA , VisP , Maas EnriquezM , PloegerBA . Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia2017;23(4):528-37. [CENTRAL: CN-01395099] [CFGD REGISTER: HA111n / HA129q] [EMBASE: 614542165]KavakliK , SaxenaK , Maas EnriquezM . Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973). Haemophilia2012;18 Suppl 3:25. [ABSTRACT NO.: PO-WE-057] [CENTRAL: CN-00883170] [CFGD REGISTER: HA111a / HA129a] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , EnriquezMM . Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results. Haemophilia2014;20 Suppl 3:94-5. [CFGD REGISTER: HA111b] KavakliK , YangR , RusenL , BeckmannH , Tseneklidou-StoeterD , Maas EnriquezM . Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis2015;13:360-9. [CFGD REGISTER: HA111c] LalezariS , TiiF , KwongYL , DelesenH , ShahA , TuckmantelC , et al. Leopold trial results: correlation of von willebrand factor antigen level with bay 81-8973 pharmacokinetic parameters of patients with severe hemophilia A. Journal of Thrombosis and Haemostasis2015;13:96-7. [CENTRAL: CN-01103566] [CFGD REGISTER: HA111f / HA129e] [EMBASE: 71944691]MahlanguJN , KavakliK , Hvitfeldt PoulsenL , Tseneklidou-StoeterD , BeckmannH , EnriquezMM , et al. Prophylactic efficacy of twice-weekly vs. 3-times-weekly bay 81-8973 in severe hemophilia A: results of the Leopold I and II clinical trials. Journal of Thrombosis and Haemostasis2015;13 Suppl 2:858. [CENTRAL: CN-01131775] [CFGD REGISTER: HA111d / HA129c] [EMBASE: 71946758]OldenburgJ , WindygaJ , HamptonK , LalezariS , Tseneklidou-StoeterD , BeckmannH , et al. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia2016;22(3):349-53. [CENTRAL: CN-01159190] [CFGD REGISTER: HA129l / HA111j] [EMBASE: 610446754]SaxenaK , KavakliK , KitchenS , OldenburgJ , YangR , BeckmannH , et al. Bay 81-8973 demonstrates comparable efficacy during prophylaxis irrespective of the assay determining potency. Haemophilia2015;21:31-2. [CENTRAL: CN-01077524] [CFGD REGISTER: HA111g / HA129g] [EMBASE: 71814436]ShahA , DelesenH , GargerS , LalezariS . Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia2015;21(6):766-71. [CENTRAL: CN-01127144] [CFGD REGISTER: HA111e / HA129d] [PMID: 25952661]YangR , SunJ , ZhaoY , WangX , WuD , Tseneklidou-StoeterD , et al. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia2019;25(3):e153-8. [CENTRAL: CN-01943371] [CFGD REGISTER: HA111m] [EMBASE: 627325629] [PMID: 30993836]">LEOPOLD II 2015</a>). In the 1976 Aronstam trial, one participant developed antigen‐negative hepatitis and was removed from the remaining duration of the trial (<a href="./references#CD014201-bbs2-0002" title="AronstamA , ArblasterPG , RainsfordSG , TurkP , SlatteryM , AldersonMR , et al. Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology1976;33(1):81-90. [CENTRAL: 13878] [CFGD REGISTER: HA4] [PMID: 773416]">Aronstam 1976</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Th\e basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>RR</b> : risk ratio; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to high risk of bias due to performance and detection bias attributed to open‐label studies.<br/>b. Downgraded once due to high levels of heterogeneity across trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prophylaxis regimen versus on‐demand treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/full#CD014201-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014201-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison between two prophylaxis regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Joint bleeds per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Joint bleeds per year (2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Spontaneous joint bleeds <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Joint bleeds per year (3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Total bleeds per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Overall bleeding frequency (bleeds per 100 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Annualised bleeding rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Total bleeding frequency (HB) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Overall bleeding frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Total bleeds per year (2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Total treatment emergent adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Rate of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison between two prophylaxis regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014201-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard prophylaxis versus investigational drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Annualised joint bleeding rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Annualised total bleeding rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard prophylaxis versus investigational drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014201-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylaxis versus on‐demand</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mean total joint bleeds per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.34 [‐46.95, ‐13.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mean change in joint health scores (CAJAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mean total bleeds per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.24 [‐64.04, ‐16.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Pain scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Radiologic measurements of joint damage (deterioration shown in eMRI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.24, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Prophylaxis versus on‐demand</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014201/references#CD014201-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014201&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014201-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014201-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014201-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014201-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD014201-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014201-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD014201-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014201-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014201-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014201"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014201"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014201"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014201\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014201\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014201"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014201&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014201';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014201/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014201/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014201%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719758087"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014201/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719758090"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014201/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df08def059371',t:'MTc0MDcxOTc1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 